GDF 15 deficiency induces a progressive Schwann cell loss in vivo and regulates their survival and migration in vitro by Walter, Sabrina
 
 
I 
 
 
Dissertation 
submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
presented by 
Master of Science in Biomedical Sciences 
Sabrina Walter 
born in Rheinberg, Germany 
Oral-examination: 13.02.2014 
 
 
 
II 
 
 
GDF-15 deficiency induces a progressive 
Schwann cell loss in vivo and regulates 
their survival and migration in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:    Prof. Dr. Hilmar Bading 
Prof. Dr. Thomas Kuner 
 
Contents 
III 
 
CONTENTS 
SUMMARY --------------------------------------------------------------------------------------------------------------------- 1 
ZUSAMMENFASSUNG ----------------------------------------------------------------------------------------------------- 2 
CHAPTER 1:  INTRODUCTION ---------------------------------------------------------------------------------------- 3 
1.1 PERIPHERAL NERVE FUNCTION AND STRUCTURE --------------------------------------------------------------- 3 
1.1.1  Glial cells of the peripheral nervous system --------------------------------------------------------- 3 
1.1.2  Schwann cell development ------------------------------------------------------------------------------ 4 
1.1.2.1  Differentiation, proliferation, survival and migration ---------------------------------------- 5 
1.1.3  Myelinogenesis --------------------------------------------------------------------------------------------- 6 
1.1.3.1  Neurotrophic factors regulating myelination -------------------------------------------------- 8 
1.1.3.2   Neuregulin is a key regulator of myelination -------------------------------------------------- 9 
1.1.4  Nerve regeneration -------------------------------------------------------------------------------------- 10 
1.1.5  Demyelinating diseases -------------------------------------------------------------------------------- 12 
1.2  GROWTH DIFFERENTIATION FACTOR-15 ----------------------------------------------------------------------- 14 
1.2.1  Gene and protein structure ---------------------------------------------------------------------------- 14 
1.2.2  Regulation of expression and tissue distribution ------------------------------------------------- 15 
1.2.3  GDF-15 signaling ----------------------------------------------------------------------------------------- 16 
1.2.4  Functional roles for GDF-15 --------------------------------------------------------------------------- 17 
1.2.4.1  GDF-15 and inflammation----------------------------------------------------------------------- 17 
1.2.4.2  GDF-15 and cardiovascular diseases -------------------------------------------------------- 17 
1.2.4.3  GDF-15 and cancer ------------------------------------------------------------------------------ 18 
1.2.4.4  GDF-15 and the nervous system -------------------------------------------------------------- 18 
1.3 AIM OF THE STUDY ------------------------------------------------------------------------------------------------- 21 
CHAPTER 2:  MATERIALS AND METHODS --------------------------------------------------------------------- 22 
2.1 ABBREVIATIONS ---------------------------------------------------------------------------------------------------- 22 
2.2 MATERIALS AND SOLUTIONS ------------------------------------------------------------------------------------- 24 
2.2.1  Materials and solutions used in the molecular biology ------------------------------------------ 24 
2.2.1.1  Materials used in molecular biology ---------------------------------------------------------- 24 
2.2.1.2  Antibodies used in molecular biology -------------------------------------------------------- 24 
2.2.1.3  Solutions used in molecular biology ---------------------------------------------------------- 25 
2.2.2  Materials, solutions and media used for cell culture --------------------------------------------- 26 
2.2.2.1  Materials used in cell culture ------------------------------------------------------------------- 26 
2.2.2.2  Solutions and media used in cell culture ---------------------------------------------------- 26 
2.2.2.3  Solutions and kits used for FACS analysis ------------------------------------------------- 27 
2.2.3  Materials and solutions used for Histology --------------------------------------------------------- 27 
2.2.3.1  Materials used for Histology -------------------------------------------------------------------- 27 
2.2.3.2  Solutions used for histology -------------------------------------------------------------------- 28 
2.3 METHODS ----------------------------------------------------------------------------------------------------------- 29 
Contents 
IV 
 
2.3.1  Mouse lines and IBF ------------------------------------------------------------------------------------- 29 
2.3.2  Molecular Biology ---------------------------------------------------------------------------------------- 29 
2.3.2.1  Genotyping ----------------------------------------------------------------------------------------- 29 
2.3.2.2  RNA extraction ------------------------------------------------------------------------------------- 32 
2.3.2.3  Reverse Transcription PCR (RT-PCR) ------------------------------------------------------ 32 
2.3.2.4  Quantitative real-time PCR (qRT-PCR) ----------------------------------------------------- 33 
2.3.2.5  Western Blot ---------------------------------------------------------------------------------------- 34 
2.3.3  Cell culture ------------------------------------------------------------------------------------------------- 35 
2.3.3.1 Collagen extraction from rat tails --------------------------------------------------------------- 35 
2.3.3.2 Coating of cell culture plates -------------------------------------------------------------------- 35 
2.3.3.3 Primary Schwann cell cultures (pSC) --------------------------------------------------------- 36 
2.3.3.4 Cell lines used -------------------------------------------------------------------------------------- 38 
2.3.3.5 Proliferation assay by FACS analysis --------------------------------------------------------- 38 
2.3.3.6 Apoptosis assay by FACS analysis ----------------------------------------------------------- 39 
2.3.3.7 Migration assay ------------------------------------------------------------------------------------- 40 
2.3.3.8 Treatment of cell lines and primary Schwann cell cultures with recombinant  
 GDF-15 and/or NRG1 Type III ------------------------------------------------------------------ 41 
2.3.4  Histological methods ------------------------------------------------------------------------------------ 41 
2.3.4.1  Perfusion of mice ---------------------------------------------------------------------------------- 41 
2.3.4.2  In vivo Schwann cell quantification ----------------------------------------------------------- 41 
2.3.4 Statistical Analysis ---------------------------------------------------------------------------------------- 43 
CHAPTER 3:  RESULTS ----------------------------------------------------------------------------------------------- 44 
3.1 PHENOTYPE ANALYSIS OF GDF15-/- MICE ---------------------------------------------------------------------- 44 
3.1.1  Schwann cell numbers are reduced in adult peripheral nerves ------------------------------- 44 
3.1.2  In vivo gene expression study: ------------------------------------------------------------------------ 47 
3.1.2.1 GDF-15 deficiency has no effect on the Neuregulin 1 type III expression in nerve 
 tissue -------------------------------------------------------------------------------------------------- 48 
3.1.2.2 GDF-15 deficiency increases the expression of ErbB2 in spinal marrow but has    
 no effect on nerve tissue ------------------------------------------------------------------------- 49 
3.1.2.3 GDF-15 deficiency has no effect on the Hmgcr expression in nerve  tissue -------- 50 
3.1.2.4  GDF-15 deficiency has no effect on the NDRG1 expression  in nerve tissue ------ 51 
3.1.2.5 GDF-15 deficiency leads to an increase of IL-6 in sciatic and femoral nerves          
 in vivo ------------------------------------------------------------------------------------------------- 52 
3.2 IN VITRO GENE EXPRESSION STUDY: ---------------------------------------------------------------------------- 53 
3.2.1 Efficient gdf15 knockdown by using two different siRNAs -------------------------------------- 53 
3.2.2 siRNA induced gdf15 knockdown has no effect on IL-6 or NDRG1  expression ---------- 53 
3.3. PREPARATION AND FUNCTIONAL STUDIES OF ADULT MOUSE PRIMARY SCHWANN CELL CULTURES -- 
  -------------------------------------------------------------------------------------------------------------------- 55 
3.3.1 Predegeneration of adult sciatic nerves and purification by trypsinization leads to pure 
 mouse adult primary Schwann cell cultures -------------------------------------------------------- 55 
Contents 
V 
 
3.3.2  Functional studies: Schwann cell proliferation, apoptosis and migration in vitro --------- 57 
3.3.2.1 GDF-15 deficiency has no effect on cell cycle progression in primary Schwann    
 cell cultures ------------------------------------------------------------------------------------------ 57 
3.3.2.3 GDF-15 deficiency leads to an increased apoptosis in Schwann cells in vitro and 
 recombinant GDF-15 promotes  Schwann cell survival ---------------------------------- 59 
3.3.2.2 GDF-15 deficiency reduces the migration of Schwann cells in vitro ------------------- 61 
3.4 GDF-15 SIGNALING IN PRIMARY SCHWANN CELLS AND IN THE SCHWANN CELL  LINE RT4-D6P2T -- 65 
3.4.1 ErbB2 inhibition has no effect on Schwann cell migration -------------------------------------- 65 
3.4.2 ErbB2 activation is involved in the signaling mechanism of GDF-15 in the Schwann cell 
 line RT4-D6P2T ------------------------------------------------------------------------------------------- 66 
CHAPTER 4:  DISCUSSION ------------------------------------------------------------------------------------------ 68 
4.1  GDF-15 DEFICIENCY REDUCES SCHWANN CELL NUMBERS IN ADULT MICE---------------------------- 68 
4.2  GDF-15 REGULATES INTERLEUKIN-6 EXPRESSION IN PERIPHERAL NERVES -------------------------- 70 
4.3  EFFICIENT ENRICHMENT OF ADULT MOUSE SCHWANN CELL CULTURES FOR USE  IN FUNCTIONAL 
 STUDIES ---------------------------------------------------------------------------------------------------------- 73 
4.4  GDF-15 PROTECTS SCHWANN CELL SURVIVAL AND MIGRATION ---------------------------------------- 75 
4.5  ERBB2 IS A PROMISING RECEPTOR FOR GDF-15 SIGNALING IN SCHWANN  CELLS ------------------ 77 
4.6      CONCLUSION ---------------------------------------------------------------------------------------------------- 79 
ACKNOWLEDGMENTS -------------------------------------------------------------------------------------------------- 80 
REFERENCES -------------------------------------------------------------------------------------------------------------- 81 
Summary 
1 
 
Summary 
 
Schwann cells are the glial cells of the peripheral nervous system (PNS) with 
multifunctional roles. Myelinating Schwann cells wrap axons with multilayered myelin 
sheaths providing electrical insulation and rapid impulse propagation. They also play 
a key role in the immune response after nerve injury and play an active role during 
nerve repair by contributing to a surrounding growth environment that allows 
peripheral nerve axons to regenerate (Rodrigues, Rodrigues et al. 2012). 
GDF-15, a neurotrophic factor and member of the TGF-β superfamily has been 
shown to support nerve regeneration (Mensching, Borger et al. 2012; Charalambous, 
Wang et al. 2013). Schwann cells express GDF-15 and seem to be an important 
source of GDF-15 in peripheral nerves (Strelau, Strzelczyk et al. 2009).  Interestingly, 
analysis of GDF-15 deficient mice showed a severe and progressive motoneuron 
loss accompanied by a loss of axons. Moreover, studies in our laboratory showed a 
hypermyelination in adult mutant mice (Dr. J. Strelau, unpublished data). Together 
these data suggest that GDF-15 affects Schwann cell.  
In this study, I first investigated the putative effect of GDF-15 deficiency on Schwann 
cells and showed for the first time that GDF-15 loss reduces Schwann cell numbers 
in adult mice. To address the question whether this observation is correlated with an 
up or down regulation of other important signaling molecules I analyzed several gene 
expression patterns in adult peripheral nerves and spinal marrow associated with 
Schwann cells and/or GDF-15. Interestingly, IL-6 expression, a key regulator of the 
immune response is upregulated in peripheral nerves. However, in vitro studies failed 
to proof the direct effect of GDF-15 knockdown on IL-6 expression in Schwann cells. 
For functional studies including GDF-15 dependent proliferation, cell death and 
migration of Schwann cells I next established a method to produce highly enriched 
adult Schwann cell cultures, showing that GDF-15 is a survival factor for Schwann 
cells and that GDF-15 deficient Schwann cells fail to migrate. Both defects were 
rescued by treatment with recombinant GDF-15.  
Since GDF-15 specific receptors are not unequivocally identified, I began to 
investigate the underlying signaling cascades well known to control myelin sheath 
growth, most notably the putative interaction of GDF-15 with ErbB2 receptor tyrosine 
kinase, expressed on Schwann cells. Here I showed the activation of the ErbB2 
receptor by recombinant GDF-15 in Schwann cells for the first time. 
Taken together, this suggests that GDF-15 constitutes an important endogenous 
regulator of Schwann cell functions in the adult. 
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Zusammenfassung 
 
Schwann Zellen sind die Gliazellen des PNS. Sie sind zuständig für die Bildung und 
den Erhalt der Myelinschichten. Ausserdem spielen sie eine wichtige Rolle in der 
Immunantwort nach einer Nervenverletzung so wie während des 
Regenerationsprozesses (Rodrigues, Rodrigues et al. 2012).  
GDF-15, ein neurotropher Faktor der zur TGF-β Superfamilie gehört, unterstüzt die 
Nerven Regeneration (Mensching, Borger et al. 2012; Charalambous, Wang et al. 
2013). Ausserdem hat die Phänotypanalyse einer GDF-15 defizienten Maus gezeigt 
das Motoneurone im adulten Tier absterben sowie das Axone verloren gehen. In 
dieser Studie wurde ebenfalls gezeigt das Schwann Zellen GDF-15 expremieren und 
es wird vermutet, das sie eine wichtige Quelle von GDF-15 in peripheren Nerven 
darstellen (Strelau, Strzelczyk et al. 2009). Weitere Untersuchungen des Phänotypes 
der GDF-15 defizienten Maus in unserem Labor haben ergeben, das es im adulten 
Stadium zu einer Hypermyelinisierung der peripheren Nerven kommt (Dr. J. Strelau, 
unveröffentlichte Daten). Aufgrund dieser Daten haben wir vermutet, das GDF-15 im 
adulten Alter Schwann Zellen beeinflusst. 
In dieser Studie habe ich das Zusammenspiel von Schwann Zellen und GDF-15 
untersucht und konnte zum ersten mal zeigen, das GDF-15 Defizienz zu einem 
Verlust von Schwann Zellen im adulten Tier führt. Aufbauend auf diesem Ergebnis 
habe ich die hoch oder runter Regulation von verschiedenen Genen, die mit 
Schwann Zellen und/oder GDF-15 in Verbindung gebracht werden, in peripheren 
Nerven analysiert. Intressanterweise, war die Expression des Entzündungmarkers 
IL-6 erhöht. Allerdings konnten in vitro Studien nicht den direkten Effekt von 
runterreguliertem GDF-15  auf die IL-6 Expression in Schwann Zellen untermauern. 
Desweiteren habe ich eine adulte Schwann Zell Kultur etabliert und funktionelle 
Studien ergaben das GDF-15 das Überleben von Schwann Zellen sichert so wie die 
Migration unterstüzt. Beide Defizite konnten durch Zugabe von rekombinanten 
GDF-15 reduziert werden. 
Da der Signalweg von GDF-15 noch nicht vollkommen bekannt ist, habe ich noch 
Signalwege untersucht die dafür bekannt sind die Myelindicke zu regulieren und 
konnte zum ersten mal zeigen, das der ErbB2 Rezeptor in Schwann Zellen durch 
rekombinantes GDF-15 aktiviert wird. 
Zusammengefasst zeigt diese Studie, das GDF-15 ein wichtiger endogener Faktor 
für adulte Schwann Zellen ist. 
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Chapter 1:  Introduction 
1.1 Peripheral nerve function and structure 
 
A peripheral nerve is build up by fascicles (nerve bundles) containing several 
neurons (nerve fibers). Nerve fibers, the smallest functional compartment within a 
nerve, are mainly made by axons and Schwann cells. They are encased by a scaffold 
of connective tissue consisting of three parts. The endoneurium encloses several 
nerve fibers creating the fascicles. It protects nerve fibers by embedding them in 
collagenous matrix from trauma. The second part is the perineurium. It engulfs 
several fascicles and functions as a diffusion barrier. The whole nerve trunk is 
surrounded by the third part, the epineurium. The nerve fiber composition classifies a 
nerve as a sensory (e.g. optical nerve), motor (e. g. femoral nerve) or mixed (e.g. 
sciatic nerve) nerve. They extend through the entire body and provide information, 
motor, sensory or autonomous to nearly every organ and as well every tissue. For 
this reason development, maintenance and repair are critical for body functions 
(Squire 2012).  
In contrast to the central nervous system (CNS), the peripheral nervous system 
(PNS) shows regenerative capability after injury as nerves residing in the periphery 
are more vulnerable to traumatic injury. The major glial cells of the PNS, the 
Schwann cells play a main role in nerve regeneration. 
1.1.1  Glial cells of the peripheral nervous system 
 
Schwann cells were first described by Theodor Schwann in 1839. There are two 
types of Schwann cells found within a peripheral nerve, non-myelinating and 
myelinating. The fate of Schwann cells depends on the size of the axons with which 
they make contact. Axons with less than 1 µm of diameter are engulfed by the 
cytoplasm of non-myelinating Schwann cells (Brinkmann, Agarwal et al. 2008). 
Several smaller axons are engulfed by one cell, building the so called Remak-Bundle 
(Fig.1.1). In contrary, myelinating Schwann cells can only wrap around one axon 
(Fig.1.1).  
Other glial cells in the PNS are the olfactory ensheathing cells, resembling 
non-myelinating Schwann cells. They ensheath the PNS as well as the CNS part of 
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primary olfactory axons. In autonomic ganglia of the gut, a third type of glial cells is 
found, the enteric glia. Teloglia are found at nerve terminals and skeletal muscle. 
They support the stability of the neuromuscular junction.  
 
1.1.2  Schwann cell development 
Most Schwann cells originate from the neural crest. However, it was shown that 
some Schwann cells in ventral roots originate from the ventral tube and that some 
Schwann cells arise from the spinal cord after the migration of the neural crest is 
complete. The Schwann cell lineage in rodents, arising from the neural crest, starts 
with Schwann cell precursors appearing at embryonic day 14 (E14). During E15 to 
E17, Schwann cell precursors convert to immature Schwann cells. By finding contact 
with outgrowing neuritis, immature Schwann cells mature reversibly to 
non-myelinating or myelinating Schwann cells directly after birth (Jessen and Mirsky 
1998).  
 
 
Figure 1.1:  Schematic il lustration of the Schwann cell l ineage. Differentiation of 
Schwann cells to myelinating or non-myelinating types is reversible. Cartoon adapted 
from (Jessen and Mirsky 2005). 
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1.1.2.1  Differentiation, proliferation, survival and migration  
 
Schwann cell differentiation, survival, proliferation and migration during development 
are controlled by different growth factors. One of the key factors is Neuregulin 
(encoded by Nrg 1-4), an epidermal growth factor (EGF)-like growth factor with a 
multifunctional role during Schwann cell development. In the early 1980s, Brocks and 
others demonstrated that cultured Schwann cells proliferate actively in the presence 
of Nrg1 whereas serum withdrawal inhibits proliferation (Brockes, Lemke et al. 1980). 
Today it is known that several aspects of Schwann cell development are influenced 
by Nrg1. In early Schwann cell lineage Nrg1 promotes glial differentiation from the 
neural crest and is required for survival of Schwann cell progenitors in vitro. Nrg 
signaling in Schwann cells is transmitted by epidermal growth factor (ErbB) 2/ErbB3 
heterodimers (Garratt, Voiculescu et al. 2000) and Nrg/ErbB2 signaling is essential 
for survival of Schwann cell progenitors. Schwann cell progenitor numbers are clearly 
reduced in ErbB2, ErbB3 or Nrg1 mutant mice (Meyer and Birchmeier 1995; 
Riethmacher, Sonnenberg-Riethmacher et al. 1997; Morris, Lin et al. 1999).  
The formation of immature Schwann cells from Schwann cell progenitors at ~E16 is 
accelerated by Nrg1, fibroblasts growth factor-2 (FGF-2) and Notch (Jessen and 
Mirsky 2005). Immature Schwann cells can, in contrary to the progenitor cells, 
support cell survival in an autocrine manner by expressing a mixture of survival 
factors. In vitro, this mixture contains neurotrophin-3, the platelet-derived growth 
factor-β and the insulin-like growth factor 2 (Meier, Parmantier et al. 1999). 
Postnatally, Schwann cell numbers have to be adjusted to axonal numbers. There is 
evidence that the axons themselves regulate Schwann cell numbers by controlling 
proliferation. In vivo, axonal contact loss decreases proliferation of Schwann cells in 
newborn animals (Komiyama and Suzuki 1992). Nrg1 is a major axonal mitogen as it 
was shown in co-culture studies of Schwann cells and neurons (Morrissey, Levi et al. 
1995). Notably, in vivo it was shown that deletion of the type II transforming growth 
factor-β (TGF-β) receptor decreases Schwann cell proliferation, demonstrating that 
TGF-βs are also a potential mitogen (Jessen and Mirsky 2005). In vivo an identified 
death signal after nerve injury in newborn animals involves the p75 neurotrophin 
receptor, possibly by binding of the neurotrophin, nerve growth factor (NGF) (Syroid, 
Maycox et al. 2000). 
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Immature Schwann cells mature to myelinating or non-myelinating Schwann cells, 
depending on the axon diameter. Axon derived Nrg1-type III is essential for Schwann 
cells to mature to myelinating Schwann cells in vitro. The transcription factors Krox20 
and Oct-6 are also promoted by Nrg (Murphy, Topilko et al. 1996; Leimeroth, 
Lobsiger et al. 2002; Taveggia, Zanazzi et al. 2005).  
Nrg1 also supports Schwann cell migration (Shah, Marchionni et al. 1994; Dong, 
Sinanan et al. 1999; Taveggia, Zanazzi et al. 2005; Aquino, Hjerling-Leffler et al. 
2006).  A zebrafish study from 2011 did not only show the importance of Nrg1 type III 
for Schwann cell migration; it also proved the importance of the ErbB2 receptors. In 
zebrafish, Schwann cell precursors, emerging from the neural crest, accumulate in 
the posterior lateral line ganglion (PLLg) and migrate as mature Schwann cells along 
the posterior lateral line nerve (PLLn). Knock down of Nrg1 reduces Schwann cell 
numbers along the PLLn. To prove the importance of the ErbB2 receptors, they made 
genetic chimeras. Interestingly, they found that reduced Schwann cell migration by 
lack of Nrg1 can be rescued by some wild type neurons in the PLLn and that the 
possession of ErbB2 receptors in Schwann cells is essential for the migration. Wild 
type Schwann cells cannot rescue their ErbB2 deficient neighbors thus proving that 
Schwann cell migration is dependent on Nrg1/ErbB2 signaling (Perlin, Lush et al. 
2011). 
 
1.1.3  Myelinogenesis  
 
Myelinating Schwann cells form bands of Bunger next to the axons, engulf it with 
their complete cell body and spirally wrap it several times. The cell membranes, lying 
on top of each other, form the myelin sheaths. During this wrapping process, the 
Schwann cells cytoplasm is pushed to the outside, leading to a compaction of the 
myelin (Fig.1.2.b). One axon is engulfed by several Schwann cells in a row so that 
small gaps, the nodes of Ranvier, are formed between the single Schwann cells 
(Fig.1.2. a). Myelin, an electrical insulator, inhibits the excitation of the myelinated 
axonal parts. Transmission of the action potentials is only possible from node of 
Ranvier to node of Ranvier allowing even small axons to conduct rapidly. The leaping 
from node to node is called saltatory conduction (Squire 2008). 
Myelin membranes built by Schwann cells in the PNS and oligodendrocytes in the 
CNS have a higher lipid to protein ratio in contrary to most other biological 
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membranes. The dry weight of myelin consists of ~70-80% lipids and only of 
~20-30% proteins. The containing lipids are cholesterol, phospholipids, galactolipids 
and plasmalogen in a ratio of 3:3:2:1 to 4:3:2:,1 whereas cholesterol synthesis 
influences myelin thickness (Saher, Quintes et al. 2011).  
 
 
Fig 1.2. Schematic representation of a) a myelinated axon with indicated nodes of 
Ranvier and b) the development of the myelin sheath by a Schwann cell.  Adapted from 
(Kettenmann and Ransom 2005). 
 
As soon as immature Schwann cells are triggered to mature to myelinating Schwann 
cells they stay in a growth arrest (Johnson, Zoubos et al. 2005) and start the 
synthesis of four myelin associated main proteins. The glycoprotein Protein-0 (P0), 
peripheral myelin Protein-22 (PMP-22), myelin-associated glycoprotein (MAG) and 
the myelin basic protein (MBP) are the main proteins (Mirsky and Jessen 1996; 
Garbay, Heape et al. 2000; Mirsky, Jessen et al. 2002). Schwann cells, without 
axonal contact express basal levels of P0 as well as MBP. This expression is 
modulated by axonal contact in vivo and in vitro (LeBlanc and Poduslo 1990; 
Morgan, Jessen et al. 1994). P0 levels are also increased by increased cAMP in vitro 
especially if growth factors like fibroblast growth factor-2 (FGF-2) are abolished 
(Morgan, Jessen et al. 1994). 
Other myelin associated proteins are proteolipid protein (PLP), CNPase and periaxin 
(Kurihara, Monoh et al. 1990; Dieperink, Oneill et al. 1992; Garbern, Cambi et al. 
1997).  
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The organization of the myelination program is the focus of several groups and some 
transcriptional regulators have been identified over the last decades. The most 
famous ones, are the zinc-finger transcription factor early growth response gene 2 
(Egr 2/Krox-20) and the POU transcription factor Oct-6 (Mirsky and Jessen 1996).  
Krox-20 deficiency leads to the absence of Schwann cell myelination. It seems that 
Krox-20 is involved in the activation of the myelination program. However, as the 
promoters of myelin genes are missing the binding sites needed for Krox-20, 
intermediate genes are needed. Another explanation is that the absence of Krox-20 
inhibits the Schwann cell lineage (Jessen, Brennan et al. 1994; Topilko, Schneider-
Maunoury et al. 1994).  
The phenotype of Oct-6 deficient mice has been studied by different groups with 
different outcomes. They agree on an altered myelination, while one group stated 
that the phenotype is similar to the Krox-20 deficient mice, another group said that 
the myelination onset is just delayed. In mice where the P0 promoter only drives a 
transcriptionally inactive form of Oct-6, myelin gene products are overexpressed 
leading to a hypermyelination (Mirsky and Jessen 1996). 
Two other known transcription factors are Pax-3, which suppresses myelin 
differentiation as Oct-6 and c-Jun, in which levels are increased after loss of axonal 
contact (Mirsky and Jessen 1996). 
 
1.1.3.1  Neurotrophic factors regulating myelination  
 
During the last decades several growth factors regulating or influencing myelin are 
known. Among them are some neurotrophic factors. They are required for the 
survival of different neuronal populations and can be roughly classified into three 
major groups. One group is the TGF-βs, which includes TGF-β1, TGF-β2, TGF-β3, 
the glial cell line derived factor (GDNF) and the growth differentiation factor-15 
(GDF-15). Several studies showed the inhibiting effect of TGF-βs on myelination. In 
purified Schwann cell cultures, cAMP induced differentiation to myelinating Schwann 
cells is inhibited by TGF-βs. It seems that TGF-βs can override axon induced as well 
as cAMP induced myelination (Mews and Meyer 1993; Einheber, Hannocks et al. 
1995; Brown, Ward et al. 2003). The inhibition mechanism is still unclear, but it is 
suggested that TGF-βs might generate non-myelinating Schwann cells in developing 
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nerves or even act in the early Schwann cell lineage maintaining the non-myelinating 
Schwann cell phenotype. Thereby regulating myelination in an indirect way (Morgan, 
Jessen et al. 1994; Griner, Joshi et al. 2013). In axons, Schwann cells and their 
precursors, several different members of the TGF-β superfamily are found. TGF-β1, 
TGF-β2 and TGF-β3 are widely distributed and TGF-β1 is upregulated after nerve 
transection (Scherer, Kamholz et al. 1993; Rufer, Flanders et al. 1994; Einheber, 
Hannocks et al. 1995). Other TGF-β superfamily members, which are found in 
Schwann cells or their precursors, are GDNF (Henderson, Phillips et al. 1994), 
BMP-6 (Mirsky and Jessen 1996) and most importantly for this work GDF-15 
(Strelau, Sullivan et al. 2000). 
Another group of neurotrophic factors are the neurotrophins including among others 
NGF, brain-derived neurotrophic factor (BDNF) and neurotrophin-3. NGF shows a 
positive effect on myelination, whereas BDNF can both, inhibit and promote 
myelination depending on the different neuron types (Xiao, Kilpatrick et al. 2009).  
Interestingly, the positive effect of NGF is restricted to the receptor tyrosine kinase 
tropomyosin-related kinase A (TrkA) positive Dorsal root ganglion (DRG) neurons. 
Co-cultures of TrkA positive neurons and Schwann cells showed enhanced 
myelination after treatment with exogenous NGF. TrkA negative neurons are not 
affected by exogenous NGF (Chan, Watkins et al. 2004). Further in vitro analysis of 
TrkA positive neurons showed the enhanced myelin production by exogenous BDNF 
(Chan, Cosgaya et al. 2001). In vivo, overexpression of BDNF leads to 
hypermyelination and increased axonal diameters (Tolwani, Cosgaya et al. 2004). 
Interestingly, exogenous BDNF shows an inhibitory effect on myelin production in 
TrkB positive neurons (Xiao, Wong et al. 2009). Notably, it is known that NGF and 
BDNF upregulate the soluble forms of Nrg1 type I and type II in TrkA positive 
neurons in vitro (Taveggia, Zanazzi et al. 2005). Whether this regulation occurs on 
the type III isoform is not known.  
 
1.1.3.2   Neuregulin is a key regulator of myelination 
 
Today it is known that Neuregulin is not only an important growth factor involved in 
Schwann cell development, it is furthermore one of the key factors of myelination. 
Nrg1 deficiency leads to significant hypomyelination (lethal at P0), while Nrg1 
overexpression leads to hypermyelination. The signaling pathway induced through 
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the epidermal growth factor receptor-2 (ErbB2) is important. Schwann cell-specific 
deletion of ErbB2 as well as Nrg1 deletion leads to hypomyelination (Garratt, 
Voiculescu et al. 2000; Michailov, Sereda et al. 2004; Chen, Velardez et al. 2006). As 
mentioned in Chapter 1.1.3, cholesterol, phospholipids, galactolipids and 
plasmalogen in a ratio of 3:3:2:1 to 4:3:2:1 constitute the myelinlipid composition 
whereas Cholesterol is 26% to 28% of dry weight in myelin (Saher, Quintes et al. 
2011). Cholesterol synthesis is essential for myelin synthesis and Schwann cells can 
synthesize the needed amount of cholesterol in situ (Saher, Brugger et al. 2005). The 
rate-limiting step in cholesterol synthesis is the formation of mevalonate which is 
catalyzed by the enzyme HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA, 
encoded by Hmgcr). Lipoprotein-deficient media induces Hmgcr expression in 
cultured Schwann cells, indicating the ability of Schwann cells to counteract low 
cholesterol levels (Fu, Goodrum et al. 1998). In 2007, Pertusa and colleagues 
analyzed the correlation of Nrg1/ErbB2 signaling and cholesterol synthesis in 
different cell lines and primary rat Schwann cells. They found out that (1) Nrg 
receptors ErbB2, ErbB3 and ErbB4 are transactivated by low cholesterol levels, (2) 
Hmgcr transcriptional activity is enhanced by overexpression of ErbB2 or ErbB3 and 
the combination of both, (3) treatment with recombinant Nrg1 type III increases 
ErbB2 and ErbB3 phosphorylation, (4) the use of ErbB inhibitors diminish Hmgcr 
promoter activity and (5) that NRG1 increases the steady-state levels of Hmgcr 
mRNA in primary rat Schwann cells. These findings prooved that Nrg1/ErbB2 
signaling controls myelin thickness by regulating cholesterol biosynthesis on a 
transcriptional level (Pertusa, Morenilla-Palao et al. 2007). 
 
1.1.4  Nerve regeneration 
 
Understanding the mechanisms of nerve regeneration is of high clinical importance. 
Between 13 and 23 per 100 000 persons each year suffer under peripheral nerve 
injuries, and their recovery is proportional to the severity of damage. Understanding 
the mechanism of nerve regeneration is the basis for a complete cure. Even though, 
Schwann cells are known as the cells responsible for myelination in the PNS, they 
also play a major role in the immune response after peripheral nerve injury and 
regeneration. They are not only involved in the remyelination stage; their active role 
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in nerve regeneration starts directly after nerve injury. Schwann cells become 
activated and re-enter the cell cycle again.  Myelin and axonal debris must be cleared 
of the injured site to support axonal growth which is done by infiltrating macrophages 
and Schwann cells. In fact, the expurgatory of myelin debris is an essential stage 
during regeneration. Myelin contains axonal growth inhibitors as NOGO-A and MAG 
(David and Lacroix 2003) and therefore, diminishes axonal regrowth. After cleaning 
the injury or inflammated site, Schwann cells form the bangs of Bunger guiding the 
newly formed axons towards the denervated targets. An extracellular matrix, 
consisting of collagen and laminin produced by Schwann cells further supports 
axonal regrowth and guidance (Evans 2001). After guidance the axon, the Schwann 
cells differentiate into myelinating Schwann cells and start to myelinate the newly 
formed axon (Stoll, Jander et al. 2002). This regeneration process is not only seen 
after traumatic injury; it has been observed in neurodegenerative disorders such as 
Alzheimers and Parkinson diseases and in demyelinating diseases such as multiple 
sclerosis (Coleman 2005). 
However, identification of the mechanisms inducing the repair response or just 
leading the Schwann cells to maintain the myelin sheaths in the adult organism is still 
at its beginning and is partly not unequivocally discussed. For example, in late 2012 it 
was shown that Nrg1 overexpression in Schwann cells restored normal myelination 
after nerve injury (Stassart, Fledrich et al. 2013). But in early 2013 it was shown that 
Nrg1 is not essential for remyelination, as it seems that in late stages of remyelination 
other pathways compensate for Nrg1 deficiency (Fricker, Antunes-Martins et al. 
2013).  
Surgical intervention in peripheral nerve injuries is mostly necessary to align the 
axonal stumps. One method is the tubulisation of the injured nerves with e.g. 
collagen, showing an enhanced repair outcome by an additional treatment with 
BDNF. Interestingly, the form of BDNF submission also alters the experimental 
outcome. Collagen tubulisation with BDNF delivered to the repair site by an osmotic 
minipump or crosslinked to the collagen matrix was compared. BDNF cross-linked to 
the collagen matrix showed the highest nerve repair. Combined treatment with CNTF 
and BDNF further enhanced functional nerve regeneration (Lewin, Utley et al. 1997).  
Another surgical method is the insertion of a nerve graft (Rodrigues, Rodrigues et al. 
2012). The use of acellular nerve allografts (ANAs) is limited as they depend on host 
Schwann cells. The host Schwann cells have to proliferate rapidly, leading to 
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senescence. The lengths of ANAs are limited, such limitation is associated with 
increasing Schwann cell senescence (Saheb-Al-Zamani, Yan et al. 2013). Therefore, 
the use of nerve grafts containing Schwann cells overexpressing neurotrophins as 
BDNF, CNTF, NT-3 or GDNF is tested (Godinho, Teh et al. 2013; Santosa, Jesuraj et 
al. 2013)  
In spinal cord injuries, Schwann cell transplantations are the up-to-date standard test 
system. Neuregulin and the TGF-β related cytokine GDNF have been shown to 
support Schwann cell migration within these test systems and enhance the repair 
outcome (Zhang, Zhao et al. 2010; Deng, Deng et al. 2013). GDNF is a very potent 
neurotrophic factor compared to other neurotrophins. GDNF is 75-fold more potent 
on supporting survival of cultured motoneurons (Zurn, Baetge et al. 1994). It was 
shown by Deng and coworkers that GDNF enhances spinal cord injury repair. The 
newly formed axons grew along the GDNF overexpressing Schwann cells and host 
Schwann cells as well as the GDNF overexpressing Schwann cells remyelinated the 
regenerated axons (Deng, Deng et al. 2013). There is also evidence that GDF-15, 
also a potent neurotrophic factor for motoneurons enhances nerve regeneration (see 
1.2.4.4). 
 
1.1.5  Demyelinating diseases 
 
Myelination disorders occur in the CNS as well as in the PNS. In the CNS the most 
recognized myelination disorder is Multiple Sclerosis (MS). In the PNS, the most 
common diseases are the Guillain-Barre Syndrome (GBS), the Charcot-Marie Tooth 
disease and Friedreichs Ataxia.  
MS is characterized by the formation of lesions in the CNS. It is an autoimmune 
disorder leading to the destruction of oligodendrocytes resulting in demyelination of 
axons. Pro-inflammatory cytokines such as TNF-α have been associated with DNA 
fragmentation in oligodendrocytes at the site of MS lesions (Lucchinetti, Bruck et al. 
2001). 
Acute inflammatory polyneuropathies are collectively called GBS. It is an 
autoimmune disorder that attacks axons and the myelin sheaths, inducing a 
demyelination that leads to a rapid progressive paralysis. Different forms of GBS are 
known. Demyelinating forms of GBS are characterized by a demyelination induced by 
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macrophages associated with T-cell and plasma cell infiltration (Chiang and Ubogu 
2013). 
The Charcot-Marie Tooth disease (CMT), also known as hereditary motor and 
sensory neuropathies is subdivided into 4 main groups whereas CMT-1 and CMT-4 
are myelination disorders. They are defined by a characteristically reduced nerve 
conduction velocity (NCV) with an accompanied axonal loss leading to a severe 
disability in adulthood (Kalaydjieva, Gresham et al. 2000; Nave, Sereda et al. 2007). 
During the second or third decade of life, neural deafness develops by muscle 
weakness and wasting, tendon areflexia and sensory loss affecting all modalities. At 
this point in time, Schwann cell dysfunctions are observed which are manifested by 
disturbed myelination such as hypomyelination and demyelination/remyelination 
leading to the reduced NCV. The Schwann cell dysfunctions are followed by a severe 
and progressive axonal loss. Further studies showed that not the demyelination itself 
but the axonal loss leads to neural deafness. Gene expression studies showed that a 
mutation in the N-myc downstream regulated gene 1 (NDRG1) is found in CMT 
patients (Kalaydjieva, Gresham et al. 2000). Furthermore, NDRG1 deficiency in mice 
leads to a similar phenotype as found in CMT patients (Okuda, Higashi et al. 2004). 
Interestingly for this work, NDRG1 expression is increased by GDF-15 
overexpression (Tsui, Chang et al. 2012). 
Another neurodegenerative, myelin-affecting disorder is Friedreichs ataxia. Primarily 
dorsal root ganglia, spinocerebellar pathways, the posterior column and the 
pyramidal tracts of the spinal cord are affected. Axons degenerate in the distal parts 
leading to a dying back manner towards the cell bodies (Hughes, Brownell et al. 
1968; Said, Marion et al. 1986; Lu, Schoenfeld et al. 2009). Today it is known, that 
this autosomal recessive disorder is induced by a mutation of the frataxin gene and it 
has been shown that the cells mostly affected by the frataxin mutation are Schwann 
cells. Frataxin deficiency induces an inflammatory toxicity to Schwann cells. Schwann 
cells die, leading to the dying back of the axons (Lu, Schoenfeld et al. 2009). 
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1.2  Growth differentiation factor-15 
 
Growth differentiation factor-15 is a distant member of the transforming growth 
factor-βs (TGF-β) family. TGF-βs are structurally related cytokines which are involved 
in the regulation of cell proliferation, differentiation, immune response and 
extracellular matrix formation. (Palladino, Morris et al. 1990; Sporn and Roberts 
1990; Bottner, Krieglstein et al. 2000). The TGF-β superfamily can be subdivided into 
4 subfamilies, the TGF-β-, Glial derived neurotrophic factor (GDNF)-, activin- and 
decapentaplegic-Vg-related (DVR)-families and Growth differentiation factor-15 
(GDF-15) (Bottner, Suter-Crazzolara et al. 1999; Strelau, Bottner et al. 2000). 
GDF-15 was discovered in the late 1990s by several groups simultaneously and is 
therefore known by different names as GDF-15 (Bottner, Suter-Crazzolara et al. 
1999), macrophage inhibitory cytokine 1 (MIC-1)(Bootcov, Bauskin et al. 1997), non-
steroidal anti-inflammatory drugs activated gene-1 (NAG -1)(Baek, Kim et al. 2001), 
PL74 (Morrish, Linetsky et al. 1996), placental bone morphogenetic protein (PLAB) 
(Hromas, Hufford et al. 1997), placental transforming growth factor-β (PTGF- β) 
(Lawton, Bonaldo et al. 1997), prostate-derived factor (PDF) (Paralkar, Vail et al. 
1998) and transforming growth factor-β placental (TGF-βPL)(YokoyamaKobayashi, 
Saeki et al. 1997). In this work, the term GDF-15 is used.  
 
1.2.1  Gene and protein structure 
 
The human gdf15 gene is located on chromosome 19 whereas the mouse gdf15 
gene is located on chromosome 8. It is consistent of two exons, separated by one 
intron within the prepeptide domain of the protein. A TATA-like motif is located near 
to the putative translation start codon (Fig.1.1) (Bottner, Laaff et al. 1999).  
The human precursor protein is consistent of 308 amino acids (aa) whereas the 
preproteins of rat and mouse are only consistent of 303 aa. The GDF-15 sequence 
similarity in the mature protein is remarkably low between species. Between the three 
species, they share only 70% conserved residues whereas in other TGF-βs as 
TGF-β1 and bone morphogenetic protein-2 (BMP-2) share 99% and 100% conserved 
residues. The protein in all three species possesses a hydrophobic signal peptide at 
the N-terminal end, a dibasic cleavage site (RGRR) and a conserved pattern of 
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cysteine’s in the C-terminal domain, the cysteine knot, a structural hallmark of the 
TGF-β superfamily (Fig.1.3) (Bottner, Laaff et al. 1999). 
 
 
Figure 1.3: gdf15 gene and GDF-15 protein structure. Note the cysteine knot, a 
structural hallmark of the TGF-βs in the mature protein. 
 
 
1.2.2  Regulation of expression and tissue distribution 
 
During the characterization of the gdf15 genes in different mammals, the promoter 
region was analyzed as well, revealing several expression regulatory elements as  
five  SP1, four AP-1, one AP-2 and NF-kB binding sites (Bottner, Laaff et al. 1999; 
Baek, Horowitz et al. 2001). Other studies showed that GDF-15 expression is 
upregulated by EGR-1(Baek, Kim et al. 2005) and p53 (Li, Wong et al. 2000). In 
2003, Yang and colleagues showed that GDF-15 concentration can also serve as a 
biomarker for p53 pathway activation (Yang, Filipovic et al. 2003). 
Alongside of the basal transcription mediators, several other factors, mediating 
GDF-15 expression were revealed. In the breast cancer cell line MCF-7, an 
overexpression of AKT upregulates GDF-15 expression (Campbell, Bhat-Nakshatri et 
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al. 2001) whereas an inhibition of PI3K and AKT induces GDF-15 in the cancer cell 
line HCT-116 (Yamaguchi, Lee et al. 2004).  
 
The majority of TGF-β superfamily members are synthesized as an inactive 
precursor protein which dimerizes in the endoplasmatic reticulum. This is also true for 
GDF-15. The homodimer of the precursor protein is then transported to the golgi 
apparatus where it is cleaved at a furine-like cleavage site. The human mature 
GDF-15 consists of 112 aa, whereas the rodent mature GDF-15 contain 115 aa 
(Bottner, Laaff et al. 1999; Bauskin, Zhang et al. 2000). 
GDF-15 is widely expressed in the adult organism. It is strongly expressed in the 
placenta and prostate. GDF-15 mRNA can be found in different epithelial cells as 
enteric, respiratory, ectodermal and endodermal epithelial cells and in activated 
macrophages (Lawton, Bonaldo et al. 1997; YokoyamaKobayashi, Saeki et al. 1997; 
Bottner, Suter-Crazzolara et al. 1999; Fairlie, Moore et al. 1999).  
In the CNS, GDF-15 is highly expressed in the choroid plexus and secreted into the 
cerebrospinal fluid (CSF) (Strelau, Sullivan et al. 2000). GDF-15 expression in the 
adult rat brain is almost exclusively in the choroid plexus whereas in newborn rats, 
GDF-15 expression is also localized in ependymal cells lining the ventricles, in the 
striatal subventricular zone and in populations of non-neuronal cells of the 
thalamic/hippocampal lamina affixa (Schober, Bottner et al. 2001). In the PNS, 
GDF-15 is expressed in Schwann cells (Strelau, Strzelczyk et al. 2009). 
 
1.2.3  GDF-15 signaling 
 
As a distant member of the TGF-β superfamily, it was assumed that the signaling 
pathway of GDF-15 is similar to those of TGF-βs. However, this hypothesis could not 
be proved and the search for the involved receptors begun. As GDF-15 is involved in 
tumor progression and cell invasion in cancer and most GDF-15 publications focus 
on GDF-15 involvement in cancer, its signaling pathway has been studied by different 
groups in cancer cell lines. They showed that GDF-15 transactivates ErbB2 in human 
breast and cancer cells by activating AKT and extracellular signal-regulated kinase 
(ERK)-1/2 (Kim, Lee et al. 2008) or steroid receptor coactivator (Src) (Park, Lee et al. 
2010). ErbB2 is also activated by Neuregulin, an important factor involved in early 
Introduction 
17 
 
myelin formation and peripheral nerve injury response (Calvo, Zhu et al. 2010; 
Newbern and Birchmeier 2010; Perlin, Lush et al. 2011; Chang, Shyu et al. 2013). 
AKT and ERK signaling is also involved in GDF-15 signaling in cerebellar granule 
neurons (CGN). It protects CGNs by activating AKT and inhibiting endogenously 
active ERK from low-potassium induced apoptosis (Subramaniam, Strelau et al. 
2003). But still, the signaling pathway of GDF-15 in the PNS, especially in Schwann 
cells, is still unclear. 
 
1.2.4  Functional roles for GDF-15 
 
Since its discovery in the late 1990s, it was shown that GDF-15 is a multifunctional 
factor involved in inflammatory processes, cardiovascular diseases and cancer. 
Interestingly, it is also a very potent neurotrophic factor. 
 
1.2.4.1  GDF-15 and  inflammation 
 
During inflammatory processes macrophages play a key role. During the search for 
factors involved in macrophage activation, Bootcov and colleagues simultaneously 
with other groups (see 1.2) discovered GDF-15, also known by the name 
macrophage inhibitory cytokine-1 (Mic-1). They showed that GDF-15 is upregulated 
by factors e.g. Interleukin-β or Interleukin-2 associated with macrophage activation 
(Bootcov, Bauskin et al. 1997). In atherosclerosis, a chronical inflammation of the 
aterial wall GDF-15 deletion as well as overexpression has protective effects (see 
1.2.4.2). 
 
1.2.4.2  GDF-15 and cardiovascular diseases 
 
Myocardial GDF-15 is rapidly increased after ischemic injury (Kempf, Eden et al. 
2006) and patients with acute myocardial infarction show elevated levels of 
circulating GDF-15 (Wollert 2007; Wollert, Kempf et al. 2007), showing the prognostic 
values of GDF-15 in cardiovascular diseases (Kehl, Iqbal et al. 2012). 
In apolipoprotein (Apo) E-deficient mice, a mouse model for progressive 
atherosclerotic lesions, GDF-15 deficiency protects from atherosclerosis 
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progresssion (de Jager, Bermudez et al. 2011; Bonaterra, Zugel et al. 2012). At the 
same time, another study showed that GDF-15 overexpression has the same effect. 
ApoE-deficient mice overexpressing GDF-15 had reduced atherosclerosis than the 
control group (Johnen, Kuffner et al. 2012). However, the mechanisms in GDF-15 
overexpression reducing atherosclerosis risk are unknown whereas the mechanisms 
in GDF-15 deficiency have been revealed. The Interleukin-6 (IL-6), an inflammatory 
marker, expression in ApoE deficient peritoneal macrophages is highly increased 
after stimulation with oxidized low-density lipoprotein (oxLDL). ApoE and GDF-15 
deficient macrophages completely lack the IL-6 induction by oxLDL stimulation 
showing that GDF-15 deficiency regulates IL-6 dependent inflammatory response to 
vascular injury (Bonaterra, Zugel et al. 2012). IL-6 expression is not regulated by 
GDF-15 overexpression (Johnen, Kuffner et al. 2012). 
 
1.2.4.3  GDF-15 and cancer 
 
As mentioned before, GDF-15 is involved in the tumorigenesis of different cancer 
types. In gastric cancer and colorectal cancer patients, GDF-15 serum levels are 
increased (Brown, Ward et al. 2003; Baek, Yoon et al. 2009). An anti-tumorigenic 
effect of GDF-15 was shown in lung, pancreatic and prostate cancer (Eling, Baek et 
al. 2006; Kadara, Schroeder et al. 2006; Kim, Kim et al. 2008; Min, Zhang et al. 
2012). In a cohort study with 94 patients suffering under intercranial tumors including 
gliomas and meningioma elevated GDF-15 protein levels were detected by ELISA in 
the cerebrospinal fluid and most interestingly, patients with elevated GDF-15 levels in 
the CSF and glioblastoma had a shorter survival showing the prognostic value of 
GDF-15 (Shnaper, Desbaillets et al. 2009). 
 
1.2.4.4  GDF-15 and the nervous system 
  
Despite the fact that GDF-15 is widely expressed in the organism, most publications 
focus on the involvement and effect of GDF-15 in cancer progression (Vanhara, 
Hampl et al. 2012; Griner, Joshi et al. 2013; Wang, Baek et al. 2013) and 
cardiovascular diseases (de Jager, Bermudez et al. 2011; Bonaterra, Zugel et al. 
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2012; Rohatgi, Patel et al. 2012). The elucidation about the physiological roles of 
GDF-15 in the CNS and PNS is still at its beginning. 
In 2000 it was shown that GDF-15 is a trophic and neuroprotective factor for midbrain 
dopaminergic neurons in vitro. It promotes survival of cultured midbrain dopaminergic 
neurons, and furthermore, it protects dopaminergic neurons against cell death 
induced by iron intoxication. Strelau and others also showed that GDF-15 protects 
nigrostriatal neurons in vivo after receiving a 6-hydroxydopamine lesion (Strelau, 
Sullivan et al. 2000). By occlusion of the middle cerebral artery in mice, an ischemic 
lesion can be induced, which leads to a direct and drastical GDF-15 mRNA 
upregulation in the hippocampus and parietal cortex as well as an upregulation of 
GDF-15 immunoreactivity in almost all neurons in the granular layer of the dentate 
gyrus. Microglial GDF-15 immunoreactivity is moderately increased (Schindowski, 
von Bohlen und Halbach et al. 2011).  Groschel and colleagues analysed GDF-15 
blood levels in patients with symptoms for acute ischemic stroke and found out that 
GDF-15 blood levels can predict the outcome 90 days after stroke. Increased 
GDF-15 levels predict an unfavorable outcome (Groschel, Schnaudigel et al. 2012). 
To further investigate the neurotrophic and neuroprotective effects of GDF-15, a 
GDF-15 deficient mouse was established (Strelau, Strzelczyk et al. 2009). Analysis of 
motoneuron numbers in the brainstem including trigeminal and facial motor nuclei 
and in spinal cord showed again the neuroprotective effect of GDF-15. Motoneuron 
numbers were decreased in GDF-15 deficient mice. At the age of 6 months, the 
deficit reached its maximum of ~20%, and most importantly for this work, it is 
accompanied by an axonal loss (~13%). Cell numbers in dorsal root ganglion were 
also reduced (Strelau, Strzelczyk et al. 2009). Another TGF-β, TGF-β2 is also known 
to promote motoneuron survival (McLennan and Koishi 2002). Trophic factors, 
required by motoneurons are mostly expressed by striated muscle and peripheral 
nerves. An mRNA study of peripheral nerves and gastrocnemius muscle indicated 
that peripheral nerves may be the most important source of GDF-15. GDF-15 
immunoreactivity in dissociated adult mouse peripheral nerve cultures were most 
intense in S100 (a Schwann cell marker) positive cells, and determination of GDF-15 
protein levels by ELISA of human Schwann cells showed that Schwann cells possess 
a high amount of GDF-15, suggesting that Schwann cells are an important source of 
GDF-15 in the peripheral nervous system. Furthermore, they showed that GDF-15 is 
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transported retrogradly along adult sciatic nerve axons (Strelau, Strzelczyk et al. 
2009). 
GDF-15 is not only important for the survival of motoneurons; it also plays a 
supporting role in peripheral nerve injury response. Charalambous and colleagues 
investigated the effect of GDF-15 on nerve regeneration. They showed that GDF-15 
expression is increased one day after nerve crush. A slightly elevated level is existent 
until 28 days post crush (Charalambous, Wang et al. 2013).  Another paper showed 
that GDF-15 substitution leads to an accelerated sensory recovery whereas the 
numbers of regenerated and myelinated axons were decreased. However, the 
recovered axons after GDF-15 treatment were further in progress showing higher 
myelinated areas and axonal diameters (Mensching, Borger et al. 2012).  
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1.3 Aim of the study 
 
In the last years, it was shown that GDF-15 is a neurotrophic factor (Strelau, Sullivan 
et al. 2000) which also supports nerve regeneration (Mensching, Borger et al. 2012). 
Motoneuron and axonal numbers are reduced in adult GDF-15 deficient mice 
(Strelau, Strzelczyk et al. 2009). Furthermore, a hypermyelination is induced (Dr. J. 
Strelau, unpublished Data).  
Schwann cells play a key role in maintaining peripheral nerves. They are involved in 
nerve immune responses (Wallerian degeneration)(Stoll, Jander et al. 2002), 
supporting nerve regrowth after injury and just by maintaining the correct myelin 
thickness. For example, in the neuropathy Charcot-Marie Tooth disease Schwann 
cell dysfunction leads to axonal loss which induces neural deafness (Kalaydjieva, 
Gresham et al. 2000). As GDF-15 deficiency induces an axonal loss and 
hypermyelination, I suggest a Schwann cell dysfunction occurring in adulthood of 
mice. 
 
To prove this hypothesis, in vivo Schwann cell numbers were determined in a 
peripheral nerve of wild type and GDF-15 mutant mice of different ages as well as 
gene expression patterns of myelin associated genes in adult peripheral nerves. 
In vitro gene expression studies were done with the help of a GDF-15 siRNA induced 
knockdown in the Schwann cell line RT4-D6P2T. 
To further elucidate effects of GDF-15 deficiency on Schwann cells, a method to 
prepare highly pure primary Schwann cell cultures from adult (6 months) mice was 
established. The cultures were used for functional studies as proliferation, apoptosis 
and migration. 
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Chapter 2:  Materials and Methods 
2.1 Abbreviations 
 
7-AAD    7-Amino-Actinomycin 
µL     micro liter 
µM     micro molar 
µmol     micro mol 
bp     base pairs 
BPE     Bovine Pituitary Extract 
Ca2+     Calcium ion 
cDNA     complementary DNA 
CNS     Central nervous system 
Ct     Cycle threshold 
DMEM    Supplemented Dulbecco´s Modified Eagle Medium 
DMSO    Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid 
dNTPs    Deoxynucleotide Triphosphates 
ECL     enhanced chemiluminiscence 
e.g.     for example 
et al.      and other (authors) 
ErbB2     epidermal growth factor receptor 2 
EtBr     Ethidium bromide 
FACS     Fluorescent associated cell sorting 
FCS     fetal calve serum 
GDF-15    Growth differentiation factor-15 
GDNF     Glial-Derived Neurotrophic Factor 
gen.     genomic 
h     hour 
IL-6     Interleukin-6 
MgCl2     Magnesium chloride 
mM     milli Molar 
mRNA    messenger Ribonucleic acid 
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NDRG1    N-my downregulated gene 1 
ng     nanogram 
NGF     Nerve growth factor 
Nrg     Neuregulin 
NTF-3     Neurotrophin-3 
PBS     Phosphate Buffer Saline 
PCR     Polymerase chain reaction 
PNS     Peripheral nervous system 
pSC     primary Schwann cell cultures 
PVP     Polyvinylpyrrolidon K30 
qRT     Quantitative real-time 
RNA     Ribonucleic acid 
rpm     Rounds per minute 
RT     Reverse transcription 
SC     Schwann cell 
Taq DNA polymerase  DNA Polymerase derived from Thermophilus 
 aquaticus 
TBE     Tris-borate-EDTA buffer 
TGF-β    Transforming growth factor-β 
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2.2 Materials and Solutions  
 
2.2.1  Materials and solutions used in the molecular biology 
2.2.1.1  Materials used in molecular biology 
 
β-Mercaptoethanol   Merck 
Agarose     Invitrogen 
Chloroform    Merck 
DNA Ladder    DNA-Marker 2-Log, New England Biolabs 
ECL-Kit    ECL Prime, Amersham GE Healthcare 
EtBr     Roth 
Ethanol    Roth 
gen. DNA extraction  QuickExtract DNA Extraction Solution 1.0, 
     Epicentre, Biozym 
Glycogen    GlycoBlue™, Ambion 
Glycerine    Merck 
Isopropanol    Appllichem 
MgCl2     Promega 
Nucleotide Mix   Promega 
PCR Buffer    PCR-Buffer green 5x, Promega 
PVDF membrane   Immobilon-P, Millipore 
Taq Polymerase   GoTaq DNA Polymerase 5 Units/µl, Promega 
TriFast    Peqlab 
Tris-HCL    Merck 
Tween20    Sigma 
 
2.2.1.2  Antibodies used in molecular biology 
 
2nd α-mouse    True Blot α –mouse HRP, Rockland 
2nd α-rabbit    Cell Signaling 
Phospho-ErbB2   Phospho-HER2/ErbB2 (Tyr877), Cell Signaling 
ErbB2     Her2/ErbB2 (M45), Cell Signaling 
β-actin    Sigma 
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2.2.1.3   Solutions used in molecular biology 
 
2x Laemmli Loading Buffer 
20.0%  Glycerine 
6.6%  β-Mercaptoethanol 
4.0%  SDS 
125 mM  Tris pH8.8 
10 mM  EDTA 
 
2x Laemmli Running Buffer 
0.25 M Tris pH8.8 
1.92 M  Glycerine 
1%   SDS 
 
10x Wet Blot Buffer 
480 mM  Tris pH8.8 
390 mM  Glycine 
 
PBS 0.1 M 
16 g   NaCl 
0.4 g   KH2PO4 
2.3 g   Na2HPO4 
in 2000 ml Milli-Q-Water  
 
TBS-T 
15 mM  NaCl 
1 mM   Tris pH8.8 
Adjust pH to 7.5 
Add 0.1% Tween20 
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2.2.2  Materials, solutions and media used for cell culture  
2.2.2.1  Materials used in cell culture 
 
Acetic acid    Acetic acid 100%, VWR 
Aseptic filter     Sterile filter 0.2 μm, Schleicher&Schuell  
BPE     Bovine Pituitary extract, BD Biosciences 
ErbB2 inhibitor   EGFR/ErbB-2/ErbB-4 inhibitor, Calbiochem 
Cell culture flask   cell culture flask T25 and T75, Greiner   
Cell culture plates   cell culture plates 6-well, 12-well, 24-well, 48-well, 
     Greiner  
Cryotubes     Cryotubes 1.8 ml, Nunc  
D-MEM    Dulbecco’s Modified Eagle Medium Gibco 
DMSO     Dimethylsulfoxide, Sigma-Aldrich  
Disposable syringes   Discardit II 5 ml and 20 ml, BD Biosciences 
GDF-15    rhGDF-15, R&D systems 
Falcon tubes    falcon tubes 15 ml and 50 ml, Greiner  
FCS     fetal calve serum, Biochrom  
Glutamine    PAA 
Hemocytometer   Neubauer  
MGM     Melanocyte Growth Medium, PromoCell 
NaCl     Sodium chloride, AppliChem  
Neuregulin    rhHeregulin α, R&D systems 
PBS     Phosphate buffered saline Dulbecco (1x) 
     (without Ca
2+
/Mg
2+
), Biochrom 
PenStrep     250 µg/mL Penicillin Streptomycin, Roche 
Trypsin    Trypsin-EDTA solution (1x), Gibco 
 
2.2.2.2  Solutions and media used in cell culture 
 
Freezing medium   90% FCS + 10% DMSO 
MCF-7 medium   D-MEM, 10% FCS, 1% PenStrep 
pSC culture medium   Melanocyte Growth Medium, 5% FCS ,1%  
     PenStrep, 5 µg ml-1 BPE 
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pSC predegeneration   D-MEM,10% FCS, 1% PenStrep 
pSC dissociation solution  D-MEM,10% FCS, 1% PenStrep, 0.125%  
     Collagenase, 1.25 U ml-1 Dispase 
RT4-D6P2T medium  D-MEM, 10% FCS, 1% PenStrep, 2 mM  
     Glutamine 
2.2.2.3  Solutions and kits used for FACS analysis 
 
7-AAD    BD Biosciences 
Annexin V binding buffer  10x Annexin V binding buffer, BD Biosciences 
APC Annexin V   BD Biosciences 
Cell dissociation   Enzyme Free Cell Dissociation Solution, Millipore 
Proliferation assay   BD Pharmingen™ BrdU Flow Kit, BD Biosciences 
 
2.2.3  Materials and solutions used for Histology 
2.2.3.1  Materials used for Histology 
 
0.1 M Na-Cacodylatebuffer pH 7.2  Merck 
Dimethylarsinacid-Na-Salt-Trihydrate   
DDSA      Serva  
DMP30      Serva  
Glutaraldehyde 25%    Merck 
Glycidether      Serva  
MNA       Serva 
Na2HPO4-Dehydrate    Merck 
NaH2PO4-Monohydrate    Merck 
Maleinacid-Na-Salt 
Na-Maleate buffer pH 6.0    Merck 
PFA      Applichem 
Procainhydrochloride    Merck  
PVP      Roth 
Toluidine Blue    Merck 
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2.2.3.2  Solutions used for histology 
 
Phosphate-Buffer 0.1 M 
5.24 g NaH2PO4-dehydrate 
28.82 g Na2HPO4-monohydrate 
in 2000 ml Milli-Q-Water, pH 7.4 
 
Paraformaldehyde 4% 
40 g Paraformaldehyde 
in 1000 ml Phosphate-Buffer 0.1 M 
 
Toluidine Blue 
1%  Borax  
1%  Toluidine Blue 
in Phosphate-Buffer 0.1 M 
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2.3 Methods 
2.3.1  Mouse lines and IBF 
 
In this work, P5 to 12 months old mice of a GDF-15 knockout/lacZ knockin (gdf15-/-) 
mouse line were used. The transfections of the embryonic stem cells were done at 
the European Molecular Biology Laboratory (EMBL, Heidelberg) and have been 
described in detail by Strelau et al. (Strelau, Strzelczyk et al. 2009). 
The gdf15-/- mouse line was crossbred with a S100β-eGFP reporter mouse line 
which was established at the University of Texas and has been described in detail by 
Zuo et al. (Zuo, Lubischer et al. 2004). It was made available by Thomas Misgeld. 
Homozygous transgenic (t/t) and gdf15-/- or gdf15+/+ mice were used for tissue 
extractions and preparation of primary Schwann cell cultures. 
Mouse lines were handled according to the Animal Welfare Act (TierSchG) and the 
breeding and care-taking were done in the Interfakultäre Biomedizinische 
Forschungseinrichtung (IBF), University of Heidelberg. 
 
2.3.2  Molecular Biology 
2.3.2.1  Genotyping 
 
Genotyping by PCR 
Mice genotyping was accomplished by extraction of genomic DNA from a tail snip 
and the amplification of a specific gene sequence.  
Tail snips needed for genomic DNA extraction were prepared in the IBF. The tail 
snips were incubated in 200 µL “QuickExtract DNA Extraction Solution 1.0“ 
(Epicentre, Biozym) for 6 minutes at 65°C followed by 2 minutes at 98°C. 2 µl of this 
DNA solution was used for the amplification of a specific gene sequence. 
The amplification was done with use of the polymerase chain reaction (PCR) 
technique, which is a method for amplification of short DNA fragments by the use of a 
heat stable DNA polymerase (Taq Polymerase) and the help of a primer pair. 
Normally, in one PCR reaction two primers (forward and reverse) are used to ensure 
an exponential amplification of the DNA fragment. In this case, a primer mix 
comsisting of two different forward and reverse primers was used.  
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One PCR reaction consisted of: 
32.0 µL Rnase free water  (Qiagen) 
10.0 µL PCR-Buffer green 5x     (Promega) 
2.0 µL MgCl2   (1 mM) (Promega) 
1.0 µL Nucleotide Mix (0.8 mM) (Promega) 
2.5 µL Primer Mix       (0.625 pmol/µl/Primer) (Metabion) 
0.5 µL GoTaq DNA Polymerase 5 Units/µl (2.5 Units) (Promega) 
48.0 µL    
+2  µL gen.-DNA         (~ 200 ng)  
 
The primer mix consisted of: 
NeoF1: 5‘-TCG CCT TCT TGA CGA GTT CT-3‘   (forward) 
R20:  5‘-CCC AGT CTT GTA GAC AGA GCA A-3‘  (reverse) 
F26:  5‘-ATG CGC ACC CAA GAG ACT-3‘    (forward) 
R21:  5‘-GGC CAC CAG GTC ATC ATA AG-3‘  (reverse) 
Product size:  gdf15+/+: 690bp  gdf15-/-: 320bp 
 
PCR conditions used are listed below. 
1. Initial denaturation   3:00 min  94°C 
2. PCR Cycles (40x) 
   Denaturation  0:30 min 94°C 
   Annealing  0:30 min 56°C 
   Extension  1:00 min 72°C 
3. Final extension       9:00 min 72°C 
4. Cooling     ∞     4°C 
 
DNA fragments were separated by gel electrophoresis. Due to the negatively 
charged phosphate group, the PCR product is attracted to the positive pole of the 
electric field. The PCR products were transferred to a 1.5% agarose gel as well as a 
DNA ladder. After the gel electrophoresis (Horizon11*14, LifeTechnologies), the 
agarose gel was stained in an Ethidium Bromide bath (30µL EtBr + 500ml distilled 
water), and the PCR products were documented with an Intas UV System.  
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Genotyping by qRT-PCR 
The genotyping for the transgenic mouse line expressing eGFP in S100β positive 
tissue was done with a qRT-PCR (see detailed description in 2.3.2.4). Shortly, 
genomic tail DNA was amplified according to the following instruction in a StepOne 
Plus Real-Time PCR system (Applied Biosystems): 
 
The following primers were used: 
 
ApoE (= Housekeeping gene) 
oIMR180:      5‘-GCC TAG CCG AGG GAG AGC CG-3‘   (forward) 
oIMR181:      5‘-TGT GAC TTG GGA GCT CTG CAG C-3‘  (reverse) 
 
eGFP (= gene of interest) 
eGFP-F: 5'-CAC ATG AAG CAG CAC GAC TT-3' (forward) 
eGFP-R:  5'-TGC TCA GGT AGT GGT TGT CG-3' (reverse) 
  
Each qRT-PCR reaction for the eGFP genotyping consisted of: 
  3.00 µl gen. DNA  
15.00 µl 2x QuantiFast SYBR Green PCR Master Mix (Qiagen) 
0.15 µl forward Primer (50 pmol/µl) (Metabion) 
0.15 µl reverse Primer (50 pmol/µl) (Metabion) 
11.70 µl RNase free water (Qiagen) 
 30.00 µl   
 
The PCR conditions were composed of three steps: 
1. PCR initial Activation step    5 min 95°C 
2. PCR cycles (45x)   
  Denaturation   20 sec 95°C 
  Annealing   60 sec 62°C 
  Extension   35 sec 72°C 
3. Dissociation curve analysis 
The mean Ct (cycle threshold) values were used for the analysis of the data by the 
comparative ∆Ct method (see detailed description in 2.3.2.4). 
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2.3.2.2  RNA extraction 
 
Cells and tissues were used for the extraction of RNA. Tissues were homogenized in 
1 ml TriFast by the use of PreCell tubes and Schwann cells were scraped off the 
culture plates after addition of 1 ml TriFast. The RNA extraction was done according 
to the user manual. The glycogen used to support the RNA precipitation was the 
GlycoBlueTM. 
 
2.3.2.3  Reverse Transcription PCR (RT-PCR) 
 
Extracted RNA was measured in BioPhotometer (Eppendorf), and 1.5 µg of the RNA 
was used for one RT-PCR reaction. The RevertAid First Strand cDNA Synthesis Kit 
was used, and the RT-PCR was carried out in an Eppendorf Mastercycler.  
 
One RT- PCR reaction was consistent of: 
1.5 µg RNA 
0.5 µL RiboLock RNase Inhibitor (20 u/µl) 
0.5 µL RQ1 DNase 
 Nuclease-free water (Qiagen) (fill up to 13 µL)
13.0 µL   
The RNA, together with an RNase inhibitor as well as DNase I, was incubated for 20 
minutes at 37°C followed by 10 minutes at 70°C before the enzyme solution was 
added. 
4.0 µL Buffer 
1.0 µL dNTP 
0.5 µL Oligo dT 
0.5 µL Random Hex 
1.0 µL Enzyme-Mix 
7.0 µL  
 
After addition of the enzyme solution, the reverse transcriptase program was started: 
10:00 min 25°C 
Transcription 
25:00 min 50°C 
5:00 min 85°C Reaction stop 
  
The cDNA were used for qRT-PCR or stored for longer periods at -20°C. 
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2.3.2.4  Quantitative real-time PCR (qRT-PCR) 
 
The quantitative real-time PCR (qRT-PCR) allows a quantitative determination of the 
amount of a specific DNA or RNA sequence by measuring the amount of the PCR 
product after each cycle. Instead of measuring the total PCR amount at a terminal 
measurement as it is done in a semi-quantitative RT-PCR.  
The synthesized cDNA was diluted 1:5 with RNase free water (Qiagen).  
 
Each qRT-PCR reaction was composed of: 
3.0 µl diluted cDNA  
6.2 µl 2x QuantiFast SYBR Green PCR Master Mix (Qiagen) 
1.3 µl QuantiTect Primer Assay (Qiagen) 
3.5  µl RNase free water (Qiagen) 
14.0 µl   
 
For each sample, three reactions were prepared in a 96 well plate.  
The StepOne Plus Real-Time PCR system from Applied Biosystems was used for the 
amplification and measuring of the PCR products. 
 
The PCR conditions were composed of three steps: 
1. PCR initial Activation step 15 min 95°C 
2. PCR cycles (40x)   
  Denaturation   15 sec 94°C 
  Annealing   30 sec 55°C 
  Extension   35 sec 72°C 
3. Dissociation curve analysis  
 
The mean Ct (cycle threshold) values and mean standard deviation were used for the 
analysis of the data by the comparative ∆Ct method. The Ct value is the cycle in 
which the fluorescence of a sample crosses the threshold. Thus, a smaller Ct value 
indicates a higher occurrence of the transcript in a sample because it is in an earlier 
cycle detectable than in samples where the Ct value for a transcript is higher 
because it is later detectable. For the comparative ∆Ct method a control sample e.g. 
RNA from untreated cells is needed. The Ct values are normalized to a 
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housekeeping gene (RPLPO). The mean Ct values of the samples of interest are 
compared to the mean Ct values of the control sample and the difference (delta Ct, 
∆Ct) between the values indicates if the gene expression had changed. In a PCR the 
gene of interest is exponentially amplified which means that the amount of the 
amplified product is doubled after each cycle.  
 
Name Symbol 
Detected 
transcript Company 
18s ribosomal RNA Rn18S NR_003278 Qiagen GmbH, 
Hilden, Germany 
Interleukin-6 IL-6 NM_031168 Qiagen GmbH, 
Hilden, Germany 
ribosomal protein, large, P0 Rplpo NM_007475 Qiagen GmbH, 
Hilden, Germany 
N-myc downstream regulated 1 Ndrg1 NM_008681 Qiagen GmbH, 
Hilden, Germany 
3-Hydroxy-3-Methylglutaryl-
Coenzym-A-Reductase 
Hmgcr NM_008255 Qiagen GmbH, 
Hilden, Germany 
Figure 2.1:   List of used predesigned qRT-PCR primers 
 
The primer used for the Nrg1 type III qRT-PCR was a self-designed primer 
purchased at the company Metabion.  
 
Nrg1 Type III primer sequence: 
(forward) 5'-CCG AGG CAT ACA CTT CAC CT-3' 
(reverse)  5'-TGT TTG TGG CTG AGT TCC TG-3' 
Product size: 224bp 
 
 
2.3.2.5  Western Blot 
 
Western blots were done as previously described (Strelau, Strzelczyk et al. 2009). 
Cells were dissolved in electrophoresis buffer (2xLaemmli) and loaded onto an 
SDS-Polyacrylamide gel. After the electrophoresis (30 mA; 2 h) of the samples, they 
were transferred to a PVDF membrane by an electroblotting overnight (350 mA, 12h, 
Wet Blot System, Amersham Biosciences). The membranes were washed in TBS-T, 
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blocked in 5% BSA in TBS-T and incubated at 4°C for 12 hours with Her2/ErbB2 
(M45) (1:1000), Phospho-HER2/ErbB2 (Tyr877) (1:1000) or β-actin (1:20000) 
respectively. Bound antibodies were detected by secondary antibodies and the ECL 
Prime Western Blotting according to the manual. 
 
2.3.3  Cell culture 
2.3.3.1  Collagen extraction from rat tails 
 
Rat tails were kindly provided by the IBF and stored at -20°C until use. Before the 
extraction of the collagen, the rat tails had to be scrubbed and stored in 70% Ethanol 
for at least 30 minutes. After disinfection, the skin was cut several times in a distance 
of 0.5 cm. The caudal vertebra were separated and snapped.  Meanwhile, the tail 
was pulled and twisted to resolve the collagen fibers. The tip of the tail was pulled of 
as well as the segmented part of the tail to expose the collagen fibers.  With the help 
of forceps, the collagen fibers were removed from the tail segments and stored in 
70% Ethanol. After the extraction of the fibers, they were washed twice with sterile 
MilliQ water and then transferred to 0.1% acetic acid (1ml 0.1% acetic acid/ 10 mg 
collagen fibers). After stirring the reagent for 3 days, it was centrifuged for 2 hours. 
The supernatant consistent of solved collagen was alliquotted and stored at 4°C. 
 
2.3.3.2  Coating of cell culture plates 
 
Some adherent cells especially primary cells need special coating of the cell culture 
plates to simulate a normal growth condition. The growth of primary mouse Schwann 
cells is best on collagen coated plates. Therefore, extracted collagen was diluted 
1:200 in sterile 0.1% acetic acid and cell culture plates were covered with the diluted 
collagen for 30 minutes. After 30 minutes the collagen solution was aspirated and the 
plates were air dried. The plates were used directly or stored at 4°C (max. 24 h). 
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2.3.3.3  Primary Schwann cell cultures (pSC) 
 
Primary adult Schwann cell cultures were prepared from peripheral nervous tissue 
from 6 months old mice. The mouse line S100β-eGFP crossbred with gdf15-/- mouse 
line was used. Therefore, both sciatic nerves were extracted and the epineurium was 
removed thoroughly under a stereomicroscope (StemiSV6, Zeiss) to reduce fibroblast 
contaminations. The use of fresh tissue results in poor Schwann cell yields. 
Therefore, extracted and purified sciatic nerve tissue was incubated for 10 days in 
10% FCS, 1% PenStrep in D-MEM (Gibco) at 37°C and 5% CO2. During the 10 days 
incubation, an in vitro pre-degeneration takes place which allows for the Wallerian 
degeneration process to begin. During a Wallerian degeneration, necrotic tissue and 
myelin debris are removed by macrophages and Schwann cells. Therefore, Schwann 
cells start to proliferate to form bands of Bungner. After 10 days, the pre-
degeneration was stopped by dissociation of the nerves in pSC dissociation solution 
for 6 hours at 37°C and 5% CO2. Tissue residues were mechanically separated into 
single cells by gentle trituration with a 1000 µl Variopipette. Cells were seeded into 
collagen (1:200) coated 12-wells plates with pSC culture medium for 48 hours (Figure 
2.2, A´-A´´´´). Even so, the epineurum was thoroughly removed, a small number of 
fibroblasts were still present and Schwann cell cultures had to be purified. The used 
purification method is based on the different attachment properties of adult peripheral 
nerve cells. Fibroblasts grow mainly flat at the cell culture surface whereas Schwann 
cells grow on top of the fibroblasts. When the cells were covered with 500 µl 
1xTrypsin-EDTA, Schwann cells detached easily within 1 minute which was observed 
through an Inversemicroscope (Axiovision, Zeiss). The reaction was directly stopped 
by adding the same amount of 100% heat-inactivated FCS. Plates with remaining 
fibroblasts were discarded (Figure 2.2, B´-B´´´´). The purified Schwann cells were 
seeded into new collagen coated 12-well plates and the purification was repeated in 
total three times with a time distance of 48 hours (Figure 2.2, C;D). 
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Figure 2.2: Purification of primary Schwann cells by trypsinisation leads to highly pure 
cultures. A´) 48 hours after plating of the predegenerated and dissociated nerves, the 
cultures consist of mostly Schwann cells and some Fibroblasts (black arrows). A´´) 
enlarged part of A´. A´´´) Schwann cell marker S100β is represented by eGFP 
expression. A´´´´) enlarged part of A´´´. B´-B´´´´) After trypsinisation most of the cells 
still attached to the plate are fibroblasts. C´-C´´´´) After one purification primary 
Schwann cell cultures only contain a few fibroblasts. D´-D´´´´) After three purification 
steps (8 days in culture), Schwann cells are ~95 % pure. scale bar: 50µm 
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2.3.3.4  Cell lines used 
 
The cell lines MCF-7 (ATCC® HTB-22™) and RT4-D6P2T (ATCC® CRL-2768™) were 
used.  The MCF-7 is a human cancer cell line, isolated from an adenocarcinoma. The 
RT4-D6P2T cell line is a schwannoma cell line derived from a rat peripheral 
neurotumor. MCF-7 cells are adherent and were cultivated in D-MEM, 10% 
heat-inactivated FCS and 1% PS at 37°C and 5% CO2. 2 mM Glutamine was added 
to the medium when used for RT4-D6P2T. Both cell lines were splitted when reached 
a confluence of ~80% by a ratio of 1:5. For longer storage periods, cell lines were 
stored at -196°C in a liquid nitrogen tank. For freezing of the cells, 5% DMSO was 
added to the normal growth medium. 
 
2.3.3.5  Proliferation assay by FACS analysis 
 
The proliferation rate of primary Schwann cells was determined by a Fluorescent 
associated cell sorting (FACS) analysis with the BD Pharmingen™ BrdU Flow Kit. 
Bromodeoxyuridine (BrdU) is incorporated into newly synthesized DNA in cells, which 
are in the S-phase. Therefore, 500 000 Schwann cells were plated out in Melanocyte 
Growth Medium, 5% FCS and 1% PS and afterwards, cultivated with 1 mM BrdU 
(10 µl BrdU solution/ml medium) for 72 hours. As a control experiment, one sample 
was cultivated with PBS instead of BrdU. The cells were trypsinized after 72h and 
stained according to the user manual. After fixation and permeabilisation, the cells 
were stored in 1% FCS in PBS at 4°C until further use. Before the cells were 
analyzed by FACS they were stained with a specific APC conjugated Antibody 
according to the manufactures guide.  
In a FACS analysis, cells are incorporated into a small liquid stream and by 
illumination with a laser beam, fluorescent light from positive cells give an electric 
signal. The amount of all cells and fluorescent positive cells respectively are 
measured. A FACS Calibur flow cytometer (BD Biosciences) was used and the FACS 
analyses were done by supervision of Dr. H. Peterziel at the german cancer research 
center (DKFZ). Quantification of data was done by the use of the FlowJo software. 
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2.3.3.6  Apoptosis assay by FACS analysis 
 
Apoptosis is characterized by energy-dependent mechanisms and morphological 
changes including loss of membrane integrity. The translocation of the membrane 
phospholipid phosphatidylserine (PS) from the inner to the outer leaflet of the plasma 
membrane is one of the earliest morphological changes that take place during 
apoptosis. The phospholipid binding protein Annexin V which can be conjugated to 
fluorochromes as APC binds to cells with exposed PS and early apoptotic stages can 
be determined by FACS. To differentiate between early and late apoptotic or necrotic 
stages, the cells of interest were counter stained with a viable dye, 7-AAD 
(7-Amino-Actinomycin). Cells positive only for Annexin V are early apoptotic and cells 
positive for both, Annexin V or 7-AAD are late apoptotic, already dead or necrotic. 
Thus, the staining with both allows a distinction between apoptosis and necrosis. 
Therefore, 500 000 primary Schwann cells in Melanocyte Growth Medium, 5% FCS 
and 1% PS were plated into one well of a 6-well cell culture plate coated with 
collagen. After 72 hours under normal growth conditions with BrdU or as control 
without BrdU the medium was transferred to 15 ml Falcon tubes and the primary 
Schwann cells were rinsed with 1x Annexin V binding buffer (BD Biosciences).  
Primary Schwann cells were removed from the plates by adding 500 µl of Enzyme 
Free Cell Dissociation Solution (Millipore) for 10 minutes followed by a rinsing step of 
the wells with 1x Annexin V binding buffer.  The cell solutions were centrifuged for 5 
minutes. The pellets were suspended in 1 ml 1x Annexin V binding buffer and 
transferred to 1.5 ml reaction tubes. Before the staining with APC Annexin V and 
7-AAD (BD Biosciences), the cell solutions were centrifuged and the pellets 
suspended in 100 µl 1x Annexin V binding buffer with 5 µl 7-AAD and 2.5 µl APC 
Annexin V.  
To ensure that the staining is specific and to adjust the FACS analysis correctly, 5 
different controls were needed. 
Therefore, 3 wells with primary Schwann cells were killed by treating the cells with 
0.8 mM H2O2 for 6 hours. Primary Schwann cells, treated with H2O2 for 6 hours were 
in a late apoptotic stage and were both, 7-AAD and APC Annexin V positive when 
stained with both.  
Two samples, one with induced Apoptosis were only stained with 100 µl 1x Annexin 
V binding buffer and 5 µl 7-AAD, two samples, one with induced Apoptosis were only 
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stained with 100 µl 1x Annexin V binding buffer and 2.5 µl APC Annexin V and the 
last control, with induced Apoptosis was stained with 100 µl 1x Annexin V binding 
buffer with 5 µl 7-AAD and 2.5 µl APC Annexin V.  
A FACS Calibur flow cytometer (BD Biosciences) was used and the FACS analyses 
were done by supervision of Dr. H. Peterziel at the DKFZ. 
 
2.3.3.7  Migration assay 
 
The used migration assay is based on the ability of cells to aggregate, to from 
spheres and on the space needed to grow. Primary Schwann cell spheres were 
formed by the hanging drop technique and plated onto collagen coated cell culture 
plates. One hour after plating out the spheres, a serial documentation of the spheres 
were started. 
First, hanging drop cultures were prepared by placing 5000 primary Schwann cells in 
15 µl Melanocyte Growth Medium, 5% FCS and 1% PS on the inside of the lid of a 
60mm culture plate. The bottom was filled with 5 ml autoclaved distilled water to 
avoid desiccation of the Schwann cell solution. By transferring the lid onto the bottom 
plate, hanging drop cultures were achieved. Some cultures were treated with 
recombinant GDF-15 (rGDF-15; 100 ng/ml) or with an ErbB2 inhibitor (working 
concentration: 0.8 ng/ml) respectively. 
The hanging drop cultures were incubated for 48 hours under normal growth 
conditions before one drop (one sphere) was transferred into one well of a 48 well 
plate coated with collagen. One hour after plating out the spheres the plate was 
transferred to a Zeiss LSM with an incubation chamber and a serial documentation 
for 36 hours was started. The area of the spheres was quantified after 0, 12, 24 and 
36 hours by the use of the area tool of the Fiji Image analysis software. In each 
experiment, at least 4 spheres per genotype and condition were analyzed. 
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2.3.3.8  Treatment of cell lines and primary Schwann cell cultures 
   with recombinant GDF-15 and/or NRG1 Type III 
 
MCF-7 and RT4-D6P2T cell were used for a receptor study. Therefore, they were 
starved overnight. The serum concentration was reduced to 0.1%. Cells were treated 
with 100 ng/ml recombinant GDF-15 or Neuregulin 1 type III for 5 minutes before 
addition of 2xLaemmli. Protein lysates were than used for Western blot analysis. 
 
2.3.4  Histological methods 
2.3.4.1  Perfusion of mice 
 
For the preparation of some histological slices, the fixation of the tissue of interest is 
needed. The most effective fixing method is the rinsing of the bloodstream of a 
narcotized mouse with freshly prepared 4% Paraformaldehyde (PFA) in 0.1 M 
Phosphate buffer. 
Therefore, mice were transferred to a chamber with a few drops of Isofluran until the 
mice started gapping. The mice were removed from the chamber and an anesthesia 
mask was put on over mouth and nose. After loss of the toe pinch response, mice 
were placed on a rack in a dorsal decubitus position. The body cavity was opened by 
incisions along the Linea Alba and towards the distal end of the forelimbs. The thorax 
was opened by cutting the diaphragm laterally at both sides and the ribs towards the 
head. The sternum was lifted until the heart was easy to access. A clamp was put on 
the tip of the left ventricle and the incarcerated part of the left ventricle was incised. A 
blunt cannula of the infusion set was placed into the incision. The right atrium was 
snipped and the blood stream was perfused with PBS until the liver and kidneys were 
anemic. Afterwards, the mice were fixed with 4% PFA for 10 minutes. The whole 
fixated animals were used for tissue extraction. 
 
2.3.4.2  In vivo Schwann cell quantification 
 
The femoral nerves were removed from gdf15+/+ and gdf15-/- mice of different ages. 
Mice in the age of 3, 6 and 12 month were perfused with 4% PFA before the femoral 
nerves were removed. Mice of the age of 5 days were killed, pinned on a cork plate 
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and the femoral nerves were exposed (Figure 2.2). The mice were then, still pinned 
on the cork plate transferred into 4% PFA. After an overnight incubation, the femoral 
nerves were removed and as well as the adult femoral nerves post-fixed with 2% 
glutaraldehyde in 0.1 M sodium cocadylat buffer. 
For the preparation of semi-thin sections the femoral nerves were embedded in an 
epoxy resin, Epon. The tissue embedding and the semi-thin sections were developed 
by Barbara Brühl according to the following embedding protocol: 
 
 Rinsing with 0.1 M Cacodylat buffer, pH 7.2 6 x 10 min 
 Post-fixation with 1% Osmium tetraoxide and 1.5% 
Potassium ferrycyanide 
1 x 60 min 
 Rinsing with 0.1 M Cacodylat buffer, pH 7.2 3 x 10 min 
 Rinsing with Sodium-maleate buffer, pH 6.0 3 x 10 min 
 Block staining in 1% uranyl acetate in Sodium-maleate 
buffer, pH 6.0 
1 x 90 min 
 Rinsing with Sodium-maleate buffer, pH 6.0 3 x 10 min 
 Dehydration in graded ethanol  
(30% - 50% - 70% - 90% - 96% - 99%)   
each 2x   5 min 
 Dehydration in absolute Ethanol 4 x 15 min 
 Propylene oxide as intermediary 2 x    5 min 
 Propylene oxide + Epon mixture (1:1) 1 x 60 min 
 Penetration with Epon 1 x over night
 Embedding in freshly prepared Epon    
 Polymerisation of the Epon 60°C 24 h 
 
Serial semi-thin sections with a distance of 20 µm were prepared at an Ultramicrotom 
(Leica) and stained with filtered Toluidine Blue. Images were taken at a Nikon Ni-E 
research microscope at the Nikon imaging centre (Bioquant Heidelberg). 
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Figure 2.3. Perfused mice with exposed femoral nerve. The square marks the area used 
for serial semi-thin sections. 
 
2.3.4  Statistical Analysis 
 
Data analysis was done in Microsofts Excel 2010 and GraphPad Prism 5 (GraphPad 
Software, San Diego, CA, USA). Datasets with Gaussian distribution were subjected 
to a two-tailed unpaired t-test. For non-Gaussian distributions, between-group 
comparisons were made using Tukey's Multiple Comparison Test. P-values <0.05 
were taken as statistical significant.   
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Chapter 3:  Results 
3.1 Phenotype analysis of gdf15-/- mice 
 
Studies in our laboratory have shown that GDF-15 deficiency leads to a progressive 
loss of facial, spinal and trigeminal motoneurons, reaching a maximum of ~20% at 6 
months and is accompanied by a loss of facial axons (Strelau, Strzelczyk et al. 2009). 
Because neuronal death and axon degeneration in debilitating diseases (including 
multiple sclerosis and Charcot-Marie-Tooth peripheral neuropathies) result from 
disruption of myelin, I started to address the question of whether myelin-forming 
Schwann cells have an impact on neuron loss in absence of GDF-15.  Therefore, 
Schwann cell numbers in peripheral nerve were quantified and some genes of 
interest were investigated. 
 
3.1.1  Schwann cell numbers are reduced in adult peripheral nerves 
 
To prove the hypothesis that GDF-15 deficiency affects Schwann cells, Schwann cell 
numbers in gdf15+/+ and gdf15-/- mice were analyzed in a peripheral nerve. The 
femoral nerve possesses motor and sensory functions, whereas the sensory part 
splits off as the saphenous nerve. The femoral nerves of P5, 3.5, 6 and 12 months 
old gdf15+/+ and gdf15-/- mice were used for the preparation of serial semi thin 
sections (Figure 3.1). 
The highest number of Schwann cells was counted in P5 old mice, when the 
myelination of the peripheral nerves is still at the beginning. A trend towards a 
reduced Schwann cell number in gdf15-/- mice starts at 3.5 months but at this time 
point, the difference did not reach significance. A significant Schwann cell reduction 
can be seen from 6 months (gdf15-/-: 68.87%) becoming more severe after 1 year 
(gdf15-/-: 47.31%) (Figure 3.2). Thus, GDF-15 deficiency leads to a Schwann cell 
loss in adult femoral nerves. 
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Figure 3.1: A) Picture of 6 months old femoral (white arrow) and saphenous nerves 
which are clearly separated by the epineurium. B) Enlarged part from panel A (white 
square) in which a myelinated axon with a Schwann cell nucleus (white arrow) is 
shown. 
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Figure 3.2: upper panel: Quantification of Schwann cell numbers in femoral nerves from 
mice of different ages and genotypes (black bars: gdf15+/+, white bars: gdf15-/-) show 
a significant reduction of Schwann cells in gdf15-/- mice starting at 6 months (student´s 
two-tailed T-test: *: p< 0.05, ***: p<0.001)  
lower panel: Data of the SC quantification with s.e.m. and student´s two-tailed t-test 
(*: p< 0.05, **: p<0.01, ***: p<0.001) 
 
  
 
 
 
 
 
 
 
 
 
 
  P5 s.e.m. 3.5 months s.e.m. 6 months s.e.m. 12 months s.e.m. 
gdf15+/+ 21.75 2.45 6.27 1.06 5.75 0.32 9.87 0.60
gdf15-/- 27.24 3.14 4.54 1.05 3.96 1.23 4.67 0.83
significance p>0.05   p>0.05  p=*   p=***   
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3.1.2  In vivo gene expression study: 
  Analysis of Neuregulin, ErbB2, Hmgcr, NDRG1 and IL-6 
 
Myelination and maintenance of myelin sheath is essential for a functional nervous 
system. In the past few years, several factors involved in myelination have been 
discovered, but its complexity and its maintenance is still not completely understood. 
Here, several factors were analyzed in vivo that have been known to be involved in 
hyper- or hypomyelination or in myelin defects. Therefore, gene expression in 
different tissues such as sciatic, femoral and facial nerves and spinal marrow (n=3) 
was analyzed by quantitative real-time PCR.  
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3.1.2.1 GDF-15 deficiency has no effect on the Neuregulin 1 type III 
expression in nerve tissue 
 
Neuregulin is a survival factor of Schwann cells during development, and it regulates 
myelin thickness. Nrg1 deficiency leads to significant hypomyelination, while Nrg1 
overexpression leads to hypermyelination. Schwann cell specific deletion of Nrg1 
leads to hypomyelination (Garratt, Voiculescu et al. 2000; Michailov, Sereda et al. 
2004; Chen, Velardez et al. 2006). The threshold level of Neuregulin is higher in 
myelinated nerves than in unmyelinated (Michailov, Sereda et al. 2004). Furthermore, 
Neuregulin enhances nerve regeneration. Neuregulin 1 type III overexpression allows 
remyelinated axons to regain normal myelin thickness (Stassart, Fledrich et al. 2013), 
similar to GDF-15 submission after nerve injury. It was shown that injured nerves 
treated with GDF-15 regenerated axons had a better quality. The myelination was 
better than in untreated animals (Mensching, Borger et al. 2012). 
Neuregulin 1 type III expression was highest in spinal marrow. However, there was 
no detectable difference between wild type and mutant tissue (Fig.3.3). 
 
 
Figure 3.3: Expression of Neuregulin 1 type III in different tissues of 6 months old 
gdf15+/+ (black bars) and gdf15-/- (white bars) mice (n=3). The box shows an enlarged 
graphic of the Neuregulin expression in peripheral nerves. The gdf15+/+ spinal marrow 
was set to 1 as calibrator. Error bars indicate s.e.m.  
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3.1.2.2  GDF-15 deficiency increases the expression of ErbB2 in 
  spinal marrow but has no effect on nerve tissue 
 
In this regard, the ErbB2 receptor is of interest. It is known that ErbB2 signaling plays 
a key role in myelination (Pertusa, Morenilla-Palao et al. 2007; Perlin, Lush et al. 
2011; Ma, Zhang et al. 2012; Chang, Shyu et al. 2013). Nrg signals through ErbB2 
and Nrg/ErbB2 signaling regulates HmgCr expression on a transcriptional level 
(Pertusa, Morenilla-Palao et al. 2007). There are also indications that GDF-15 signals 
through ErbB2 in different cancer cell lines (Kim, Lee et al. 2008; Park, Lee et al. 
2010; Joshi, Brown et al. 2011). 
Interestingly, ErbB2 was highest expressed in the femoral nerve, but a difference 
between gdf15+/+ and gdf15-/- was only existent in the spinal marrow. It is 
significantly increased in gdf15-/- tissue (Fig.3.4). 
 
 
 
Figure 3.4: Nerves, especially the femoral nerve, express more ErbB2 than spinal 
marrow. But a difference between gdf15+/+ and gdf15-/- mice was only seen in the 
spinal marrow. ErbB2 expression is increased in the spinal marrow of gdf15-/- mice. 
The gdf15+/+ spinal marrow was set to 1 as calibrator. Error bars indicate s.e.m. 
(student´s two-tailed T-test **: p< 0.01) 
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3.1.2.3 GDF-15 deficiency has no effect on the Hmgcr expression in 
nerve  tissue 
 
Neuregulin, signaling through ErbB2, regulates myelin thickness by regulating the 
expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (encoded by Hmgcr). This 
factor is the rate-limiting step in cholesterol synthesis, and the importance of a 
functional cholesterol homeostasis on the myelination has been shown in several 
publications over the last years (Pertusa, Morenilla-Palao et al. 2007; Saher, Quintes 
et al. 2009). 
Hmgcr expression level was highest in spinal marrow, and the lowest expression 
level was measured in sciatic and facial nerves. However, no significant differences 
were observed by comparing wild type and mutant mice (Figure 3.5). 
Thus, it seems that GDF-15 deficiency has no effect on Hmgcr expression in nerve 
tissue in vivo.  
 
 
Figure 3.5: Expression of Hmgcr in different tissues of 6 months old gdf15+/+ (black 
bars) and gdf15 -/- (white bars) mice (n=3). The gdf15 +/+ spinal marrow was set to 1 
as calibrator. Error bars indicate s.e.m. 
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3.1.2.4   GDF-15 deficiency has no effect on the NDRG1 expression 
 in nerve tissue 
 
N-myc downstream-regulated gene 1 (NDRG1) has been associated with the 
Charcot-Marie Tooth disease type 4D (CMTD-T4D), a myelination disorder 
(Kalaydjieva, Gresham et al. 2000). Furthermore, NDRG1 deficiency leads to both a 
defect in myelin maintenance and a Schwann cell dysfunction (Okuda, Higashi et al. 
2004) and most interestingly GDF-15 overexpression induces an upregulation of 
NDRG1 expression in cancer cells (Tsui, Chang et al. 2012).  
In this experiment, kidney tissue was also analyzed because NDRG1 is highly 
expressed in kidney tissue and GDF-15 levels are increased during chronic kidney 
disease (Breit, Carrero et al. 2012).  
NDRG1 expression was as previously shown highest in kidney and femoral tissue. 
The lowest expression is in the spinal marrow. However, no significant differences 
were observed by comparing wild type and mutant mice (Figure 3.6). 
Thus, it seems that GDF-15 deficiency has no effect on NDRG1 expression in nerve 
tissue in vivo. 
Figure 3.6: Expression of NDRG1 in different tissues of 6 months old gdf15+/+ (black 
bars) and gdf15 -/- (white bars) mice (n=3). The gdf15 +/+ spinal marrow was set to 1 
as calibrator. Error bars indicate s.e.m.   
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3.1.2.5  GDF-15 deficiency leads to an increase of IL-6 in sciatic and 
   femoral nerves in vivo  
 
GDF-15 is a stress-responsive cytokine, and several publications over the last years 
have shown a correlation between GDF-15 and Interleukin-6 (IL-6) (Bonaterra, Zugel 
et al. 2012; Tsui, Chang et al. 2012). IL-6 is an important cytokine in the immune 
response (Naugler and Karin 2008) and in peripheral nerve injuries Schwann cells 
play an important role in the immune response. Therefore, it was tested if GDF-15 
deficiency leads to a defect in Schwann cells and/or nerve immune responses by 
regulating IL-6 expression. 
IL-6 expression was highest in spinal marrow but differences between gdf15+/+ and 
gdf15-/- were only seen in sciatic and femoral nerves. The IL-6 expression was 
significantly increased in gdf15-/- sciatic and femoral nerves. Thus, GDF-15 
deficiency increases IL-6 expression in sciatic and femoral nerves, indicating an 
altered immune response in vivo (Figure 3.7). 
 
 
Figure 3.7: Expression of IL-6 in different tissues of 6 months old gdf15+/+ (black bars) 
and gdf15-/- (white bars) mice (n=3). The gdf15+/+ spinal marrow was set to 1 as 
calibrator. Error bars indicate s.e.m. (student´s two-tailed T-test *: p< 0.05) 
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3.2 In vitro gene expression study: 
 gdf15 knockdown in the Schwann cell line RT4-D6P2T and its 
 effect on IL-6 and NDRG1 expression levels 
 
By analyzing gene expression from nerve tissues, different cell types are analyzed 
and furthermore, the effect of GDF-15 deficiency on the expression level may no 
longer be measurable anymore. Therefore, a siRNA GDF-15 knockdown was 
induced in pure Schwann cells, the Schwann cell line RT4-D6P2T and gene 
expression of GDF-15, IL-6 and NDRG1 was measured 24h post transfection. In a 
publication from 2002, Hai et al. analyzed several Schwann cell lines for their myelin 
gene expression patterns and the RT4-D6P2T as well as the rat derived cell line S16 
were most suitable (Hai, Muja et al. 2002).  
 
3.2.1  Efficient gdf15 knockdown by using two different siRNAs  
 
Three different siRNA knockdown experiments with duplicates were done. 
RT4-D6P2T cells were transfected with a negative control siRNA and two different 
siRNAs called gdf-2 and gdf-3. As controls, untreated RT4-D6P2T cells and 
RT4-D6P2T transfected with an unspecific siRNA (negative control) were used.  As 
GDF-15 is a stress-responsive cytokine, its expression was increased due to the 
stress that cells undergo during transfection. Nevertheless, the use of the siRNA 
gdf-3 and the combination of the siRNAs gdf-2 and gdf-3 induced a significant 
knockdown of GDF-15 expression 24h post transfection (Figure 3.8). Thus, 
RT4-D6P2T cells with siRNA induced GDF-15 knockdown are suitable as in vitro 
model system for gene expression analysis.  
 
3.2.2  siRNA induced gdf15 knockdown has no effect on IL-6 or NDRG1
  expression 
 
Even so, a strong and significant gdf15 knockdown was induced by transfection with 
siRNAs; it had no effect on the expression of NDRG1 or IL-6.  
The data gained from three independent siRNA knockdowns were similar, concerning 
the IL-6 expression. But by comparing all three experiments together and by 
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analyzing each experiment individually no significant differences were induced by 
GDF-15 knockdown. 
Considering the NDRG1 expression, the data set from experiment 1 and 2 were 
similar but in the data set from experiment 3, the NDRG1 expression was greatly 
increased. However, by comparing the data from each experiment individually, no 
significant differences could be observed (Figure 3.8).  
 
 
Figure 3.8: Upper panel: GDF-15 expression in untreated RT4-D6P2T cells and in 
siRNA transfected RT4-D6P2T cells. The transfection with an unspecific siRNA induced 
an increase in GDF-15 expression, but the GDF-15 expression was stil l significantly 
knocked down by the use of the siRNA gdf-3 and the combination of siRNAs gdf-2+3 
(n=3). The untreated cells were set to 1 as calibrator. Error bars indicate s.e.m. 
(Tukey's Multiple Comparison Test: *: p<0.05). 
lower Panel: gdf15 knockdown has no effect on the expression of IL-6 and NDRG1 
(n=3). Error bars indicate s.e.m. 
 
 
 
 
 
Results 
55 
 
3.3. Preparation and functional studies of adult mouse primary Schwann cell 
 cultures  
 
To further elucidate possible dysfunctions that led to a Schwann cell loss in GDF-15 
mutant mice, I studied proliferation, apoptosis and migration of primary Schwann 
cells in vitro.  
 
3.3.1  Predegeneration of adult sciatic nerves and purification by 
  trypsinization leads to pure mouse adult primary Schwann cell 
  cultures  
 
First, primary Schwann cell cultures from mouse adult nerves were needed. 
Normally, Schwann cell cultures are prepared from sciatic nerves from neonatal 
animals, mostly rats. In the past few years, publications have shown preparations of 
adult rat or human Schwann cells (Haastert, Mauritz et al. 2007). Nevertheless, adult 
mouse primary Schwann cell cultures were needed and this method had to be 
established. 
The method used here is based on the principle of the Wallerian degeneration and  
on the different attachment properties of fibroblasts and Schwann cells on coated 
culture plates. A detailed description of the established method can be found in 
chapter 2.3.3.3. 
FACS analysis of 33 different Schwann cell cultures showed a Schwann cell purity of 
~95% (Figure 3.9). 
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Figure 3.9: A) Schwann cell culture after 3 purification steps. No fibroblasts were 
remaining. Scale bar: 50µm B) 33 mouse adult primary Schwann cell cultures were 
tested. They have a purity of ~ 95% (s.e.m.: 0.79). In the example histograms, analysis 
of a Schwann cell culture is shown. The Schwann cell/fibroblast population was marked 
(left, 85%) and 96.1% were Schwann cells (eGFP positive). 
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3.3.2  Functional studies:       
  Schwann cell proliferation, apoptosis and migration in vitro 
 
Our previous data have shown that GDF-15 deficiency led to a significant decrease 
of Schwann cells in vivo. Schwann cell numbers are regulated by proliferation and 
apoptosis as well as their migratory potential, and members of the transforming 
growth factor-β (TGF-β) superfamily have been demonstrated to control these 
functions  (Parkinson, Bhaskaran et al. 2004; Jessen and Mirsky 2005; Ribeiro-
Resende, Koenig et al. 2009). Thus, it is reasonable to hypothesize that GDF-15 
might affect Schwann cell numbers by regulating proliferation, death and/or 
migration. In this context, I analyzed primary Schwann cell cultures derived from wild 
type and GDF-15 mutant mice.   
 
3.3.2.1   GDF-15 deficiency has no effect on cell cycle progression in 
   primary Schwann cell cultures  
 
During Schwann cell development, it has been shown that TGF-βs affect Schwann 
cell proliferation in vivo (Jessen and Mirsky 2005). To analyze GDF-15 dependent 
cell cycle progression I started to evaluate BrdU incorporation into newly synthesized 
DNA (Figure,3.10, A) and DNA stained with 7-AAD (Figure 3.10, B).  
In average, 5.17% gdf15+/+ Schwann cells and 4.87% gdf15-/- Schwann cells were 
BrdU positive and therefore, went through S-Phase of the cell cycle within 48h. 
However, the number of proliferating wild type and mutant Schwann cells was not 
different (Figure 3.10 A).  
An investigation of the cell cycle by assessing 7-AAD staining (Figure, 3.10 B) 
revealed that, only two peaks could be seen clearly: one at around 200 representing 
cells in the G1/G0 phase and one at around 0, representing cells undergoing 
apoptosis (Sub-G1 peak). Cells in S, G2 or M phase are hard to distinguish and are 
referred to as S-G2-M. All cells behind the G1 peak are in S-G2-M. Cell cycle 
analysis confirmed that most cells are not entering cell cycle. However, an analysis of 
the data revealed a significant increase in the Sub-G1 peak in mutant Schwann cells, 
thus indicating an increase in apoptosis. 
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Figure 3.10: gdf15+/+ and gdf15-/- Schwann cells show no difference in their cell cycles 
A) Incorporation of BrdU into newly synthesized DNA did not show a difference in 
proliferation rates in gdf15+/+  (black bars) and gdf15-/- (white bars) Schwann cells. A 
measurement histogram is shown as an example in the left panel. B) Cell cycle analysis 
of gdf15+/+ and gdf15-/- Schwann cells based on the 7-AAD staining did not show a 
difference. However, an increase in the Sub-G1 peak was observed in the gdf15-/- 
Schwann cells indicating an increased apoptosis rate. 
Data are shown from 5 independent experiments (student´s two-tailed T-test: *<0.05). 
Error bars indicate s.e.m. 
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3.3.2.3  GDF-15 deficiency leads to an increased apoptosis in 
 Schwann cells in vitro and recombinant GDF-15 promotes 
 Schwann cell survival 
 
To further elucidate the increased Sub-G1 peak representing cells undergoing 
apoptosis, wild type and mutant Schwann cells were analyzed with respect to their 
apoptosis by staining with APC conjugated Annexin V. Apoptosis is characterized by 
morphological changes. One of the earliest morphological changes in apoptosis is 
the translocation of phosphatidylserine (PS) from the inner to the outer leaflet of the 
plasma membrane. Annexin V binds to cells with exposed PS, and early apoptotic 
cells can be stained by Annexin V conjugated to APC. 
By analyzing gdf15+/+ Schwann cells (Figure 3.11, A), it was observed that most 
Schwann cells were localized in the lower left quadrant. Those cells are negative for 
7-AAD (a viable dye) as well as for APC-Annexin V; they are non-apoptotic.  Only a 
few Schwann cells were localized in the lower right quadrant; they are positive for 
APC-Annexin V and are apoptotic. Schwann cells in the upper right quadrant are 
both 7-AAD and APC-Annexin V positive and are late apoptotic or necrotic.  
A comparison of gdf15+/+ and gdf15-/- Schwann cells clearly reveals that the distinct 
population seen in gdf15+/+ Schwann cells is more scattered. This demonstrates that 
the gdf15+/+ cells have more APC-Annexin V positive cells (and therefore more 
apoptotic Schwann cells) which is reduced by a treatment with recombinant GDF-15 
(100 ng/ml) (Figure 3.11, C). As GDF-15 is highly expressed by Schwann cells, wild 
type Schwann cells were not treated (Strelau, Strzelczyk et al. 2009). 
Statistical analysis showed that the increased apoptosis (~44.4 %; s.e.m. 7.78%) in 
mutant Schwann cells reached significance in four out of five independent 
experiments and that mutant Schwann cells could be rescued by treatment with 100 
ng/ml recombinant GDF-15, reaching significance in two out of three experiments. 
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Figure 3.11: GDF-15 deficiency increases apoptotic cell numbers in Schwann cells. 
A-C) Dot plots of APC-Annexin V/7-AAD stained Schwann cells. A) Most cells are 
located in the lower, left quadrant (viable cells) whereas in B) cells are scattered in the 
lower left (viable cells) and right (apoptotic cells) quadrants. C) After treatment of 
mutant Schwann cells with 100 ng/ml recombinant GDF-15, the cell population is shifted 
towards the lower left quadrant (viable cells) D) Statistical analysis proofs an increased 
apoptosis in mutant Schwann cells which can be rescued by treatment with recombinant 
GDF-15. 
Gdf15+/+ apoptosis rate was set to 1 calibrator. Error bars indicate s.e.m. (Tukey's 
Multiple Comparison Test: *: p<0.05) 
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3.3.2.2  GDF-15 deficiency reduces the migration of Schwann cells 
   in vitro 
 
Schwann cell migration is important during the nerve regeneration process. For 
example the formation of bands of Bunger (for which adequate Schwann cell 
migration is required) guides the newly formed axons. In 2009, Ribeiro-Resende et 
al. have shown that a combination of neuregulin (NRG), nerve growth factor (NGF) 
and TGF-β support the Schwann cell alignment during the formation of Bands of 
Bungner, thus supporting the migratory ability of Schwann cells (Ribeiro-Resende, 
Koenig et al. 2009). A zebrafish study demonstrated the importance of Neuregulin for 
the Schwann cell migration (Perlin, Lush et al. 2011) and another study showed that 
Neuregulin enhances nerve regeneration by supporting Schwann cell migration.  As 
GDF-15 treatment also enhances nerve regeneration (Mensching, Borger et al. 
2012), I suggest that GDF-15 controls Schwann cell migration. 
Figure 3.12 shows wild type (left panel) and mutant (right panel) Schwann cell 
spheres at different time points after plating.  Schwann cells start to migrate out and 
away from the spheres (expansion of spheres).  
The area of the expanded spheres (Figure 3.13, A) differed greatly between wild type 
and mutant Schwann cells starting at time point 12h (Figure 3.13, B). After 36h, the 
area of wild type Schwann cell spheres were increased ~59.3 times whereas the 
area of mutant Schwann cell spheres was only increased ~30.5 times, a reduction of 
45.8% compared to wild type Schwann cells. Moreover, treatment with 100 ng/ml 
exogenous recombinant GDF-15 partially restored the migration abilities. Compared 
to untreated mutant Schwann cell spheres, treated mutant Schwann cell spheres 
expanded ~138%. However, after four independent experiments, the partial rescue 
did not reach significance. By analyzing each experiment individually, the rescue 
reaches significance. 
Additionally I compared the sphere diameters from the beginning (T: 0h) and at the 
end of the experiments (T: 36h) (Figure 3.13, C). Wild type Schwann cell spheres 
were significantly decreased after 36h (~53%), suggesting that Schwann cells went 
out of the spheres into the surrounding area, whereas mutant Schwann cell sphere 
sizes were not significantly reduced. In contrast, mutant Schwann cell spheres 
treated with exogenous recombinant GDF-15 showed reduced sphere diameters 
(~65.7%) comparable to wild type spheres, demonstrating that treatment with 
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exogenous recombinant GDF-15 restores the migration ability in mutant Schwann 
cells in vitro (Figure 3.13, C).  
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Figure 3.12: Images of Schwann cell spheres 0, 12, 24 and 36 hours after plating out. 
The left panel shows a gdf15+/+ sphere and the right panel a gdf15-/- sphere. A 
reduced migration behavior can be clearly seen in the gdf15-/- sphere. 
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Figure 3.13: A) Representative Schwann cell sphere images with marked spheres 
(white lines) and expansion of Schwann cells (dashed white line). B) GDF-15 deficiency 
(square marks, n=7) leads to a significant decreased expansion of Schwann cell 
spheres which is partially rescued by the treatment with 100ng/ml recombinant GDF-15 
(triangle marks, n=4). C) After 36h, the sphere size is significantly decreased in 
gdf15+/+  Schwann cells (black bars) whereas the sphere size in gdf15-/- Schwann cells 
(grey bars) is only significantly decreased after treatment with 100 ng/ml recombinant 
GDF-15. Size of gdf15+/+ spheres at 0h was set to 1 as calibrator. Error bars indicate 
s.e.m. (Tukey's Multiple Comparison Test: *: p<0.05, **: p<0.01, ***: p<0.001) 
Results 
65 
 
3.4 GDF-15 signaling in primary Schwann cells and in the Schwann cell 
 line RT4-D6P2T 
So far, we know that GDF-15 deficiency leads to a reduced Schwann cell number in 
peripheral nerves due to reduced migration ability and an increased apoptosis rate in 
Schwann cells. However, the analysis of the myelin associated factors NDRG1 and 
HmgCr did not show any difference, whereas the expression of the pro-inflammatory 
cytokine IL-6 was increased in GDF-15 deficient sciatic and femoral nerves in vivo. 
Thus, the mechanisms which lead to a reduced Schwann cell numbers and altered 
Schwann cell behavior are still not understood. Furthermore, it is still unclear which 
receptor is involved in GDF-15 signaling in Schwann cells. To further elucidate the 
involved mechanisms, a possible candidate, the ErbB2 receptor, was studied. 
 
3.4.1  ErbB2 inhibition has no effect on Schwann cell migration 
 
Several publications have shown that a treatment with recombinant GDF-15 activates 
the ErbB2 receptor in cancer cell lines, as SK-BR-3 (Kim, Lee et al. 2008; Park, Lee 
et al. 2010; Joshi, Brown et al. 2011). Furthermore, it was shown that ErbB2 signaling 
plays a key role in myelination (Pertusa, Morenilla-Palao et al. 2007; Perlin, Lush et 
al. 2011; Ma, Zhang et al. 2012; Chang, Shyu et al. 2013) and most importantly that 
Schwann cell migration depends on ErbB2 signaling in zebrafish (Perlin, Lush et al. 
2011; Chang, Shyu et al. 2013). 
Functional effects of ErbB2 signaling on primary Schwann cells were investigated by 
a migratory assay in which Schwann cells were treated with an ErbB inhibitor. In 
theory, the blockage of ErbB2 by the use of an ErbB inhibitor should alter wild type 
Schwann cell migration as GDF-15 deficiency does. Therefore, mutant and wild type 
Schwann cell spheres were treated with an ErbB Inhibitor which was also used for 
other mouse Schwann cell studies (Heermann, Schmucker et al. 2011).  
Mutant Schwann cells again showed a decreased migration compared to wild type 
Schwann cells. However, the use of the ErbB inhibitor did not reduce wild type 
Schwann cell migration (Figure 3.14). 
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Figure 3.14: Wild type and mutant Schwann cell spheres were observed in a time lapse 
experiment over 36h, and the expansion of Schwann cell spheres was measured after 
0,12, 24 and 36h. Treatment with ErbB inhibitors did not reduce the migration compared 
to the DMSO treated control groups. Size of wild type spheres at 0h was set to 1 as 
calibrator. Error bars indicate s.e.m. (Tukey's Multiple Comparison Test: *: p<0.05, 
**: p<0.01) 
 
3.4.2  ErbB2 activation is involved in the signaling mechanism of GDF-15 
  in the Schwann cell line RT4-D6P2T 
 
ErbB2 phosphorylation was shown by western blotting of cell lysates from MCF-7 
cells, a human cancer cell line and RT4-D6P2T cells, a rat Schwannoma derived cell 
line. Due to the lack of available phospho-ErbB2 antibodies, no cell lysates from 
primary Schwann cells of mice were used. The MCF-7 cells were used as positive 
control to establish a functional western blot method. As already shown, treatment 
with Nrg (a factor highly involved in early myelination) induced a phosphorylation of 
the ErbB2 receptor in the MCF-7 cells. However, treatment with GDF-15 did not 
activate ErbB2 in MCF-7 (Figure 3.15, A) but rather lead to an ErbB2 phosphorylation 
in the Schwann cell line in four out of six experiments (Figure 3.15, B). 
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Figure 3.15: A MCF-7 cells were treated with 100ng/mL recombinant Neuregulin or 
GDF-15 for 5 minutes resulting in a phosphorylation of ErbB2 in the Neuregulin treated 
cells. The ErbB2 western blot shows the same protein amounts in the different samples. 
B RT4-D6P2T cells were treated with 100 ng/mL recombinant Neuregulin or GDF-15 for 
5 minutes, resulting in a phosphorylation of ErbB2 in the GDF-15 treated cells in four 
out of six experiments. The β-actin western Blot shows the same protein amounts in the 
different samples. 
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Chapter 4:  Discussion  
 
Schwann cells play a key role in nerve regeneration and are important during every 
stage of the regeneration process, starting with the early immune response. They are 
responsible for the phagocytosis of axonal and myelin debris, guidance of the newly 
formed axons to the distal parts of the injury and finally remyelination of the new 
axons. However, remyelinated axons fail to gain back the normal myelin thickness. 
Nerve regeneration is a complex process and limited to the severity of injury 
(Rodrigues, Rodrigues et al. 2012).  Elucidation of the regeneration mechanism has 
just begun. It was shown that overexpression of Neuregulin, an important factor 
during Schwann cell development and myelination, restores normal myelin thickness 
after remyelination (Fricker, Brelstaff et al. 2011). Interestingly, Neuregulin 
expression is increased by the neurotrophic factors NGF and BDNF (Taveggia, 
Zanazzi et al. 2005). GDF-15 is another promising factor. It was not only shown that 
GDF-15 is a neurotrophic factor in vitro and in vivo (Strelau, Sullivan et al. 2000; 
Subramaniam, Strelau et al. 2003; Strelau, Strzelczyk et al. 2009); it was also shown 
that GDF-15 expression is increased after nerve crushes (Charalambous, Wang et al. 
2013) and that submission of recombinant GDF-15 enhances nerve regeneration 
(Mensching, Borger et al. 2012). Notably, further investigation of the neurotrophic 
effects of GDF-15, also showed that GDF-15 deficiency does not only induce a 
progressive motoneuron loss in adulthood, it furthermore induces an axonal loss 
(Strelau, Strzelczyk et al. 2009) and hypermyelination of peripheral nerves (Dr. Jens 
Strelau, unpublished data) suggesting regulatory effects of GDF-15 on Schwann 
cells. The here presented work focuses on the effect of GDF-15 deficiency on 
Schwann cells in vivo and in vitro.  
 
4.1  GDF-15 deficiency reduces Schwann cell numbers in adult mice 
 
Myelination of developing nerves starts at birth when myelin inducing factors as 
axonally derived Neuregulin triggers immature Schwann cells to differentiate into 
myelinating mature Schwann cells. Schwann cell numbers are now regulated by 
survival and proliferation of immature Schwann cells controlled by Schwann cell 
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mitogens as Neuregulin and TGF-βs (Jessen and Mirsky 2005). To further elucidate 
the effects of GDF-15 deficiency on Schwann cells, total cell numbers in peripheral 
nerves at different ages (P5-12 months) of wild type and GDF-15 deficient mice were 
quantified and compared in this work. As expected, five day old mice possess more 
Schwann cells than compared to adult mice. At that age, the myelinogenesis is still at 
its beginning. Most Schwann cells are still non-myelinating and only differentiation 
into myelinating Schwann cells leads them to exit the cell cycle (Jessen and Mirsky 
2005). An in vitro study of the colonization of distal parts of sympathetic axons 
showed the importance of high Schwann cell numbers. Reduced Schwann cells 
numbers inhibited Schwann cell migration towards the distal parts of the axons 
(Heermann, Schmucker et al. 2011). Another study showed that at the age of 6 days, 
apoptotic Schwann cells can be seen which occur only occasionally at the age of 
three weeks and none are seen at the age of three months (Grinspan, Marchionni et 
al. 1996). This correlates with the total Schwann cell numbers in peripheral nerves 
quantified here. In 3.5 months old mice, Schwann cell numbers were highly reduced 
compared to those of the newborn animals, whereas there is no difference between 
the different adult stages in the wild type mice. However, by comparing cell numbers 
in wild type and GDF-15 mutant mice, mutant mice show a Schwann cell loss 
detectable at 3.5 months of age and reaching significance at six months. At the age 
of 12 months, Schwann cell loss is even more severe. Mutant mice only possess 
about 50% Schwann cells compared to wild type mice. Prior studies in our laboratory 
showed that only about 13% of axons are missing in six months old GDF-15 mutant 
mice and that a motoneuron loss starts at 4.5 months, getting more severe till the age 
of 12 months (Strelau, Strzelczyk et al. 2009). It seems that the axonal loss just 
started and will continue with progressing age as the motoneuron loss and the here 
showed Schwann cell loss. This hypothesis is supported by the progression of the 
neuropathy Charcot-Marie Tooth disease in which Schwann cell dysfunctions lead to 
axonal loss. This disease is induced by a nonsense mutation in the Ndrg-1 gene 
(Kalaydjieva, Gresham et al. 2000). Interestingly, a correlation between GDF-15 and 
NDRG1 was shown in a study from Tsui and colleagues. Overexpression of GDF-15 
induced an upregulation of NDRG1 in a cancer cell line (Tsui, Chang et al. 2012). A 
possible regulation of NDRG1 by GDF-15 deficiency in peripheral nerves is 
discussed in the following section. 
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4.2  GDF-15 regulates Interleukin-6 expression in peripheral nerves  
 
As discussed in the previous section, the here presented work shows that GDF-15 
deficiency reduces Schwann cell numbers in adults. A publication from 2012 by 
Mensching et al. showed that substitution of recombinant GDF-15 supports nerve 
regeneration by enhancing the quality of repaired axons (Mensching, Borger et al. 
2012). As Schwann cells play an important role in nerve regeneration, it is of interest 
to analyze possible correlations of GDF-15 deficiency and factors known to be 
regulating Schwann cell functions and myelin especially during the regeneration 
process. Today several factors are known which regulate Schwann cell development 
(e.g. the growth factor Neuregulin and members of the TGF-β superfamily (Jessen 
and Mirsky 2005)), myelination (e.g. Neuregulin (Jessen and Mirsky 2005)) and some 
factors involved in nerve regeneration (e.g. GDF-15 (Mensching, Borger et al. 2012), 
NDRG1(Hirata, Masuda et al. 2004)).  
Strelau and coworkers showed the neurotrophic role of GDF-15 on motoneurons and 
the loss of DRG neurons in GDF-15 deficient mice (Strelau, Sullivan et al. 2000). In 
this coherence it is of interest that the neurotrophic factors NGF and BDNF 
upregulate Neuregulin 1 type I and type II in DRG neurons (Esper and Loeb 2004). 
Neuregulin regulates the cross talk between the axon and the Schwann cells, 
defining the myelin sheath thickness (Taveggia, Zanazzi et al. 2005) and it is 
suggested that Neuregulin and its receptor ErbB2 regulate myelination by controlling 
the cholesterol synthesis on a transcriptional level (see 1.1.3.1 for more details).  
(Pertusa, Morenilla-Palao et al. 2007). Notably, as shown in this work that GDF-15 
deficiency induces a Schwann cell loss in adulthood, Berciano and colleagues 
showed that cholesterol synthesis inhibition leads to an autophagic cell death in 
mature Schwann cells (Berciano, Calle et al. 1998). ErbB2, the receptor activated by 
Neuregulin and involved in the control of cholesterol synthesis is also activated by 
treatment with recombinant GDF-15 in some cancer cell lines (Kim, Lee et al. 2008; 
Park, Lee et al. 2010). Thus, it is possible that ErbB2 is activated by GDF-15 in the 
nervous system as well. Interestingly, it was not only shown that Neuregulin regulates 
myelinogenesis, it was further more shown by Stassart et al. that mice, 
overexpressing the Neuregulin 1 isoform type III were able to restore myelin 
thickness after nerve crushes whereas myelin repair in wild type mice results in 
reduced myelin thickness (Stassart, Fledrich et al. 2013). Notably, a similar effect 
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was shown for GDF-15. Its submission after nerve injuries induced a better quality of 
regenerated axons (Mensching, Borger et al. 2012). These data, the effects of 
Neuregulin on nerve regeneration, ErbB2 activation by Neuregulin and GDF-15 as 
well as transcriptional control of cholesterol synthesis and that inhibition of 
cholesterol synthesis leads to a Schwann cell death suggest that GDF-15 deficiency 
involves a similar pathway as the Neuregulin-ErbB2 signaling. In this relation, I 
analyzed the expression of Neuregulin 1 type III, ErbB2 and Hmgcr (encoding the 
enzyme which is the rate limiting step in cholesterol synthesis) in adult wild type and 
GDF-15 mutant peripheral nerves. Although the above discussed data strongly 
suggest a correlation between GDF-15 and Neuregulin or its myelin regulating 
pathway, neither Neuregulin 1 type III, ErbB2 nor Hmgcr expression were altered by 
GDF-15 deficiency in adult nerves. Thus it seems that the pathway leading to the 
here showed reduced Schwann cell number in mutant nerves is different than the 
Neuregulin-ErbB2-Hmgcr pathway. Notably, another member of the TGF-β family, 
GDNF upregulates Neuregulin expression in DRG axons and this effect is rapidly 
occurring within minutes after treatment (Esper and Loeb 2004). As the effect of 
GDNF is very rapid but the Schwann cell loss in GDF-15 mutant mice is a very slow, 
continuous process taking several months, it is unlikely that expression differences of 
Neuregulin, ErbB2 or Hmgcr are responsible for the Schwann cell loss. However, 
ErbB2 signaling and the effect of GDNF in correlation with GDF-15 deficiency will be 
discussed in more detail later on. 
Besides Neuregulin, another interesting and promising factor is NDRG1. As already 
mentioned, a nonsense mutation in the NDRG1 gene causes the Charcot-Marie 
Tooth disease, a peripheral neuropathy in which Schwann cell dysfunction leads to 
axonal loss (Kalaydjieva, Gresham et al. 2000). NDRG1 is also involved in the 
terminal differentiation of Schwann cells during nerve regeneration, showing an 
increased expression of NDRG1 at the stage of remyelination after nerve crushes 
(Hirata, Masuda et al. 2004). Similar to NDRG1, Charalambus et al. showed an 
increased GDF-15 expression after nerve crushes (Charalambous, Wang et al. 
2013). Notably, Tsui and colleagues showed a regulation of NDRG1 and Interleukin-6 
expression by GDF-15.  GDF-15 overexpression increases the NDRG1 expression in 
cancer cells (Tsui, Chang et al. 2012). But as shown in the here presented work, in 
mature GDF-15 wild type and mutant nerves, no difference of NDRG1 expression in 
correlation with the different genotypes was observed. These data show that GDF-15 
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deficiency has now effect on the NDRG1 expression in uninjuried nerves. However, 
future studies should address the question if GDF-15 deficiency affects the increased 
NDRG1 expression after nerve injury.    
As mentioned is the passage above, Tsui and coworkers did not only show the effect 
of GDF-15 overexpression on the NDRG1 expression. They also showed that 
GDF-15 regulates Interleukin-6, the key regulator of inflammatory response, 
expression in cancer cells (Tsui, Chang et al. 2012) similar as it was shown by 
Bonaterra and colleagues in macrophages (Bonaterra, Zugel et al. 2012). In the here 
presented study, by comparing IL-6 expression in GDF-15 wild type and mutant adult 
peripheral nerves, an increase in IL-6 expression is seen in the mutant nerves. This 
demonstrates an altered immune response induced by GDF-15 deficiency in 
peripheral nerves. A publication focusing on IL-6 involvement in the nervous system 
showed that increased IL-6 expression kills frataxin-deficient Schwann cells. Frataxin 
mutation causes the neurodegenerative disease Friedreich´s ataxia (Lu, Schoenfeld 
et al. 2009). In light of my observations that Schwann cell numbers are reduced and 
that IL-6 expression is increased in GDF-15 deficient peripheral nerves and that IL-6 
kills frataxin-deficient Schwann cells, one important question arises: Is the Schwann 
cell loss in GDF-15 deficient mice similarly induced as the death of frataxin-deficient 
Schwann cells? Does the increased IL-6 expression kills GDF-15 deficient Schwann 
cells? A question, that needs to be addressed in further studies.  
To further elucidate the effects of the here observed increased IL-6 expression it is 
interesting if the Schwann cells are responsible for the increased IL-6 expression. 
Since IL-6 expression was investigated in whole peripheral nerve lysates, it is not 
known in which cell type, including Schwann cells, macrophages, fibroblasts and 
neurons, IL-6 expression is increased. Nevertheless, Schwann cells express and 
secrete GDF-15 and are suggested to be an important source of GDF-15 in the 
peripheral nerve (Strelau, Strzelczyk et al. 2009). Thus, in this work IL-6 expression 
after an induced GDF-15 knockdown was investigated to further elucidate the direct 
effect of GDF-15 deficiency in cells used to threshold levels of GDF-15. Wild type 
cells were transfected with siRNAs, inducing gdf15 knockdown. siRNA studies 
require a high cell number therefore, because the cell number is limited in primary 
Schwann cell cultures, the Schwann cell line RT4-D6P2T was used. Due to the 
stressful process of transfection an increased expression of GDF-15 could not be 
avoided. Nevertheless, a significant gdf15 knockdown was achieved compared to the 
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control situation. However, IL-6 expression was unaltered and did not show a 
correlation with GDF-15 knockdown in Schwann cells. This suggests that the 
increased IL-6 expression in peripheral nerve lysates is not Schwann cell derived; 
whether other neuronal cell types express IL-6 under the influence of GDF-15 must 
be further investigated. Moreover, a siRNA induced knockdown only reduced the 
GDF-15 expression to 25%. As Schwann cells are suggested to be an important 
source of GDF-15 (Strelau, Strzelczyk et al. 2009), it is possible that the residual 
level of GDF-15 expression is high enough to maintain the normal threshold level of 
IL-6. This test system should be further optimized in future studies, for example, by 
the blockage of the residual secreted GDF-15 by the submission of a monoclonal 
antibody against GDF-15 as described by Johnen and coworkers (Johnen, Lin et al. 
2007).  
 
4.3  Efficient enrichment of adult mouse Schwann cell cultures for use 
 in functional studies 
 
In the siRNA studies, the limiting factor for the use of primary Schwann cells was the 
amount of required cells. For functional analysis like proliferation, apoptosis and 
migration a lower cell number is needed and primary Schwann cells can be used. 
Several publications focus on preparation of primary Schwann cell cultures (Lopez 
and De Vries 1999; Haastert, Mauritz et al. 2007; Kaewkhaw, Scutt et al. 2012; Tao 
2013). However, mostly neonatal animals are used as tissue source; of these most 
are rats. Only a few publications are based on the use of adult tissue (Haastert, 
Mauritz et al. 2007). The challenging part in adult Schwann cell culture preparation is 
a low cell yield and fibroblasts which overgrow Schwann cell numbers caused by a 
higher proliferation rate. This work presents a Schwann cell preparation and 
cultivation method leading to high cell numbers and efficient and easy enrichment of 
Schwann cells and reduction of fibroblasts. It leads to ~95% pure Schwann cell 
cultures within 4 weeks.  
Preparation methods, established for neonatal material, result in a low Schwann cell 
yield by the use of adult tissue, as neonatal nerves possess a higher number of 
Schwann cells than adult nerves (see above). The here established method 
enhances the outcome by inducing the Wallerian degeneration. The Wallerian 
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degeneration is induced by extraction of the nerve from the mice and culturing in 
vitro. During the Wallerian degeneration Schwann cells re-enter the cell cycle and 
start to proliferate again (Johnson, Zoubos et al. 2005), leading to a high number of 
Schwann cells in the nerves. This step is also used in the method established for 
adult human and rat Schwann cell cultures by Haastert and coworkers (Haastert, 
Mauritz et al. 2007). While extracting the nerves, one other step is important: the 
thorough removal of connective tissue, the source of fibroblasts. However, a 
complete removal of the connective tissue is not possible and some fibroblasts will 
still remain in the cultures.  
Several purification methods for Schwann cell cultures are known but they are 
established for neonatal or human and rat cultures. Schwann cells from neonatal 
cultures are purified by the use of cytosine arabinoside, an antimitotic reagent (Yuan, 
Zhang et al. 2013) or by treatment with an anti-Thy1 antibody and complement serum 
(Ji, Shen et al. 2012). These methods involve a more often medium change, and this 
is the limiting stage for the here needed adult mouse cultures. Adult mouse Schwann 
cells detach very easily, even by changing the medium. Thus, these methods lead to 
a high Schwann cell loss and are unsuitable for adult cultures. Haastert et al. used 
another purification method for adult rat and human cultures the so called “cold jet” 
method. As already mentioned adult Schwann cells detach easily. When they are 
rinsed with ice cold PBS, Schwann cells detach and can be transferred to new plates. 
Fibroblasts are still adherent and remain in the old plate (Haastert, Mauritz et al. 
2007). Even so, the “cold jet” method is suitable for rat and human adult Schwann 
cells; it is unsuitable for mouse adult cultures as they do not survive the stress 
induced by the “cold jet” method. Without stress induced death of Schwann cells, a 
short trypsin-EDTA treatment leads to the same result as the “cold jet” method. The 
fibroblasts which grow flat at the bottom stay attached to the plates whereas the 
Schwann cells, growing on top of the fibroblasts detach within less than a minute of 
trypsin-EDTA treatment. This fast and easy purification method results in ~95% pure 
Schwann cell cultures which are suitable as an in vitro model for functional analysis.  
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4.4  GDF-15 protects Schwann cell survival and migration 
 
The established method, discussed in the passage above is an efficient method to 
produce enough primary Schwann cell material for functional studies. To further 
elucidate the importance of GDF-15 on Schwann cells, proliferation, survival and 
migration were investigated in wild type and mutant Schwann cell cultures. 
Even though it was shown by Ridley and coworkers that other members of the 
TGF- β family, TGF-β 1 and 2, stimulate rat Schwann cell proliferation in vitro (Ridley, 
Davis et al. 1989), the proliferation studies in the here presented work demonstrated 
that GDF-15 deficiency has no proliferative effect on cultured Schwann cells. 
Interestingly, another publication showed that TGF-β has dual effects on Schwann 
cell proliferation depending on the duration of the cultures. Short-term cultures 
showed increased proliferation whereas long-term cultures showed reduced 
proliferation after TGF-β submission. This publication showed the multifunctional 
effects of TGF-β family members on Schwann cells (Eccleston, Jessen et al. 1989). It 
would be of interest if there is also a correlation on proliferation in short-                     
and long-term cultures regarding GDF-15 deficiency. This should be part of future 
studies.  
Schwann cell survival is regulated amongst others by Neuregulin. Syroid and 
colleagues showed that serum withdrawal induced cell death is counteracted by the 
application of Neuregulin on postnatal Schwann cells in vitro (Syroid, Maycox et al. 
1996; Li, Tennekoon et al. 2001). The here presented work shows a similar effect 
regarding GDF-15. GDF-15 deficient cultures possessed a higher number of 
apoptotic Schwann cells than the wild type cultures, and more importantly, they 
regained a lower apoptotic cell number after GDF-15 submission, showing the 
survival protective effect of GDF-15 on Schwann cells. Although, the survival 
protecting effect of GDF-15 here shown in vitro strongly suggests that the Schwann 
cell loss in mutant nerves observed in vivo is due to an increased apoptosis, further 
in vivo studies are needed to support these in vitro data. An approach is a TUNEL 
assay and histochemical analysis of peripheral nerves in wild type and mutant mice 
as described by Grinspan and coworkers (1996). They showed that Schwann cells in 
developmental nerves undergo apotosis after axotomy which is prevented by the 
submission of Neuregulin, verifying the Schwann cell protecting effect of Neuregulin 
in vivo, which was already shown in vitro (Grinspan, Marchionni et al. 1996). Analysis 
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of apoptotic Schwann cells in GDF-15 wild type and mutant nerves after axotomy is 
also of interest considering the nerve regeneration supporting effect of GDF-15 as 
shown by Mensching and coworkers. They showed that treatment with recombinant 
GDF-15 enhanced the quality of repaired axons but which mechanism supports                     
nerve regeneration after GDF-15 treatment is not yet clear (Mensching, Borger et al. 
2012).  
During nerve regeneration Schwann cell migration is essential. They have to migrate 
towards myelin and axonal debris to clean the injury site (David and Lacroix 2003) 
and afterwards adequate migration is essential for axon guidance (Evans 2001). 
Chang and colleagues showed that rats treated with Neuregulin after an end-to-side 
neurorrhaphy had a better functional recovery than the control group. Neuregulin 
enhanced the Schwann cell migration and spreading by the activation of the ErbB2 
receptor (Chang, Shyu et al. 2013). As discussed under 4. 3, the here established 
Schwann cell culture method enhances the outcome by inducing an in vitro 
predegeneration and Schwann cells undergo similar changes as induced by nerve 
injury. Interestingly, GDF-15 regulates Schwann cell migration in those cultures. 
GDF-15 deficient cells only migrated around 50% compared to wild type cells and 
submission of recombinant GDF-15 partially rescued Schwann cell migration. 
GDF-15 is not the only member of the TGF-β family regulating Schwann cell 
migration GDNF also supports Schwann cell migration (Cornejo, Nambi et al. 2010; 
Deng, Deng et al. 2013) and nerve regeneration (Deng, Deng et al. 2013). Deng and 
coworkers showed the facilitated regeneration of Spinal cord injuries by the use of 
GDNF-overexpressing Schwann cells. GDNF supports the propriospinal axon 
regeneration and synapse formation (Deng, Deng et al. 2013). Even though, I 
showed that GDF-15 controls Schwann cell migration and it was shown by Cornejo 
and colleagues that GDNF also supports Schwann cell migration and it was shown 
that both factors support nerve regeneration (Mensching, Borger et al. 2012; Deng, 
Deng et al. 2013), a correlation of controlled Schwann cell migration by GDF-15 or 
GDNF and the nerve regeneration supporting effect has still to be shown. But 
migration investigations in vivo in mammals are hindered by methodological 
limitations such as the inaccessibility of time-lapse imaging of peripheral nerves.  
Heerman and coworkers established an in vitro assay simulating in vivo conditions by 
investigating the migration of Schwann cells along axons of sympathetic ganglion 
explants. They dissected superior cervical ganglia from mice at embryonic day 16.5 
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or 18.5 and placed them on a collagen matrix. By treatment with NGF neurite 
outgrowth was induced and Schwann cell migration along the axons was 
documented by time-lapse imaging (Heermann, Schmucker et al. 2011). As the onset 
of the GDF-15 deficient phenotype starts in adulthood and the neuron loss is specific 
on motoneurons, dorsal root ganglia (DRG) dissected from adult mice should be 
used in this assay. DRGs in the adult organism are integrated and completely 
surrounded by the spinal cord. To dissect uninjured adult DRGs is therefore a difficult 
procedure. Nevertheless, this is an in vitro assay close to in vivo conditions and 
should be established and investigated in future studies.   
 
4.5  ErbB2 is a promising receptor for GDF-15 signaling in Schwann 
 cells 
 
To further investigate GDF-15 mediated mechanisms controlling Schwann cell 
migration, a promising receptor, the ErbB2 receptor was inhibited in a migration 
assay. As mentioned above, it was shown that Schwann cell migration is regulated 
by Neuregulin and furthermore, it was shown that the signaling pathway of 
Neuregulin is essential. In zebrafish, a deletion of the ErbB2 receptor reduces 
Schwann cell migration similar as Neuregulin deletion (Perlin, Lush et al. 2011) and a 
study from Chang and colleagues showed that ErbB2 is activated by Neuregulin, 
facilitating nerve regeneration by speeding up Schwann cell migration (Chang, Shyu 
et al. 2013). The signaling pathway of GDF-15 is not unequivocally identified. There 
is proof that GDF-15 signaling involves the ErbB2 receptor in cancer cell lines as 
GDF-15 treatment leads to phosphorylation of ErbB2 (Kim, Lee et al. 2008; Park, Lee 
et al. 2010). However, on neural tissue, there was no evidence so far that GDF-15 
activates ErbB2. In this work, the ErbB2 receptor was blocked pharmacologically in a 
migration assay to show that wild type Schwann cell motility is altered similarly to that 
of GDF-15 mutant Schwann cells but wild type cell motility was not reduced by ErbB2 
inhibition. Notably, the effect of altered ErbB2 function on Schwann cell motility 
concerning Neuregulin signaling is already controversially discussed. In contrary to 
the above mentioned publications, Neuregulin/ErbB2 signaling only indirectly affects 
Schwann cell colonization of sympathetic axons by controlling Schwann cell numbers 
(Heermann, Schmucker et al. 2011), and furthermore, ErbB2 signaling is dispensable 
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after nerve injury (Atanasoski, Scherer et al. 2006).  As GDF-15 enhances the quality 
of repaired axons after nerve injury (Mensching, Borger et al. 2012) it also seems that 
the ErbB2 receptor is not essential for the enhanced nerve regeneration by GDF-15. 
If other receptors or pathways compensate for the loss of the ErbB2 receptor is not 
known. However, ErbB2 signaling is still of interest. Previous studies showed that 
only low levels of ErbB2 signaling are needed for Schwann cell motility (Meintanis, 
Thomaidou et al. 2001) and the pharmacological inhibition of ErbB2 signaling may 
still allow residual activity as already discussed by Heermann et al. (Heermann, 
Schmucker et al. 2011). To ensure that there is no ErbB2 activity during the migration 
assay, the use of ErbB2 deficient Schwann cells would be the best choice. However, 
other factors, for example GDNF (Cornejo, Nambi et al. 2010), NGF (Anton, 
Weskamp et al. 1994) or IGF-1(Cheng, Steinway et al. 2000) could compensate for 
the inhibited GDF-15/ErbB2 signaling as a slight increase of migration is seen in the 
inhibitor treated wild type cells. Mutant cells treated with the ErbB2 inhibitor did not 
show any effect, suggesting that GDF-15 influences Schwann cell migration by a 
complex coregulation of different factors and/or signaling pathways. Whether different 
factors and/or other receptors compensate the ErbB2 inhibition needs to be 
addressed in future studies. 
Next to the functional study, the migration assay, ErbB2 activation by recombinant 
GDF-15 in Schwann cells was investigated on the protein level. Due to the lack of 
antibodies reactive to mouse derived tissue, the rat derived Schwann cell line 
RT4-D6P2T (the same Schwann cell line used for the siRNA studies) was used. The 
here presented work shows the activation of ErbB2 in Schwann cells by treatment 
with recombinant GDF-15 for the first time. Thus, further investigation of the 
functional influence of ErbB2 on GDF-15 controlled Schwann cell migration gains an 
even higher importance. A side from the functional study, further elucidation of the 
ErbB2 activation of GDF-15 has to be part of future studies. Even though, there are 
no available antibodies against ErbB2 and activated ErbB2 reactive to mouse tissue, 
future studies should establish an assay to measure ErbB2 activity in primary 
Schwann cells; for example by the use of an antibody detecting tyrosine 
phosphorylation of membrane proteins.  A similar approach was done by Chang et al. 
(Chang, Shyu et al. 2013). 
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4.6   Conclusion 
 
This is the first study showing the physiological and significant role of GDF-15 on 
mature Schwann cells. In the adult organism, GDF-15 deficiency induces a 
progressive Schwann cell loss and an altered immune response in peripheral nerves, 
showed by increased IL-6 expression. Functional studies by the use of the here 
established adult Schwann cell cultures showed that GDF-15 deficiency induces 
apoptosis and that migration is strongly reduced in deficient cells. Both deficits could 
be rescued by a treatment with recombinant GDF-15. Furthermore, this work shows 
the activation of the ErbB2 receptor by GDF-15 in Schwann cells for the first time. 
Further studies should address the question, if the increased IL-6 expression is 
responsible for the in vivo Schwann cell loss induced by GDF-15 deficiency as 
similarly seen in frataxin-deficient Schwann cells. 
Furthermore, future studies should determine whether the nerve regeneration 
enhancing effect of GDF-15 submission as shown by Mensching and colleagues 
(Mensching, Borger et al. 2012) is Schwann cell dependent as the here presented 
work shows the regulation of Schwann cell survival and migration by GDF-15. Both, 
survival and adequate migration is essential for nerve regeneration. 
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